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Summary 
An important next step to Tuberculosis control relies on the translation of basic science and 
modern diagnostic techniques into primary health care clinics. These assays must be rapid, 
inexpensive, interpretation of results must be easy and they must be simple so that a healthcare 
worker with limited training can perform the tests under safe conditions. This study consists of 
four aims. The first aim was to develop a methodology to sterilize sputum specimens for rapid 
TB diagnosis and drug resistance testing. Candidate bactericides were identified from the 
literature, and tested for their bactericidal activity in Mycobacterium tuberculosis. We identified 
ultraseptin®aktiv as a powerful bactericidal agent which sterilizes sputum specimens for 
subsequent safe handling prior to light emitting diode microscopy and it also provides a DNA 
template for PCR-based tests. An algorithm has been proposed for the processing of specimens 
and rapid diagnosis of TB and drug resistant TB while patients wait for results. 
 
Recently, the World Health Organization has endorsed the MTBDRplus test for diagnosis of TB 
and drug resistant TB. However genotypic tests may have more problems than anticipated. With 
the HIV pandemic, an increase of non-tuberculous mycobacteria has been reported. The 
sensitivity of genotypic tests in specimens with underlying non-tuberculous mycobacterial 
species therefore requires further evaluation. This study therefore also aimed at determining the 
reliability of the MTBDRplus assay for detection of drug resistant TB where non-tuberculous 
bacterial load is high. Clinically relevant non-tuberculous mycobacterium DNA and DNA from a 
multi-drug resistant TB isolate were obtained. Ratios of the different NTM with the MDR-TB 
DNA were made and subjected to the MTBDRplus assay. Known mix NTM and TB infected 
clinical isolates and sputum sediments were also evaluated for TB and drug resistance detection 
on the MTBDRplus assay. Under these conditions, this study provides evidence that the 
MTBDRplus test cannot reliably detect TB and drug resistance TB in specimens with underlying 
non-tuberculous mycobacteria. 
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Thirdly, to evaluate the sensitivity of the MTBDRplus assay for detecting drug resistance in 
hetero-resistant isolates, ratios were made using purified DNA from an MDR and pan-
susceptible TB isolate. The MTBDRplus assay was then performed on the different ratios. We 
report that the MTBDRplus assay can efficiently detect wild type DNA in genes associated with 
resistance during the early evolution of drug resistance. However, in the later stage during 
treatment when both the wild type and mutants are present, the detection limit for the mutant 
DNA was 1:55. Due to these results, the MTBDRplus assay should still be further improved or 
other tests should be developed to address these limitations.  
And finally to combat cross amplicon contamination during the final steps of genotypic detection 
with the MTBDRplus assay, a proof of concept for a patentable closed tube line probe device 
was proposed on the 4th aim. This device can be improved to enable automated drug resistance 
genotyping of multiple specimens.  
 
The results of this study highlight the need for a sensitive inexpensive point of care drug 
resistance test that does not require intensive training. 
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Opsomming 
'n Belangrike volgende stap om Tuberkulose te beheer is om basiese wetenskap resultate te 
gebruik sodat moderne diagnose tegnieke ontwikkel kan word wat in primêre gesondheidsorg 
klinieke toegepas kan word. Hierdie toetse moet vinnig, goedkoop, en die interpretasie van 
resultate moet maklik wees. Die toetse moet eenvoudig wees sodat 'n gesondheidswerker met 
beperkte opleiding die toetse onder veilige omstandighede kan uitvoer. Hierdie studie bestaan uit 
vier doelwitte, waarvan die eerste was om „n metode te ontwikkel vir die sterilisasie van sputum 
monsters vir vinnige TB diagnose en die toesting van middelweerstandigheid. Kandidaat 
kiemdodende middels was geïdentifiseer vanaf die literatuur en die middels se kiekdodende 
aktiviteit was getoets op Mycobacterium tuberculosis. Ons het ultraseptin®aktiv geïdentifiseer as 
'n kragtige kiemdodende middel wat bakteria in sputum monsters steriliseer vir veilige hantering 
voordat diagnose met n lig uitstralende diode mikroskopie gedoen kan word. Hierdie 
behandeling met ultraseptin®aktiv bied ook 'n DNA templaat vir PCR-gebaseerde toetse. 'n 
Algoritme is voorgestel vir die hantering van monsters en die vinnige diagnose van sensitiewe- 
en middel weerstandige Tuberkulose terwyl die pasiënte by die kliniek wag vir die resultate.  
 
 
Onlangs het die Wêreld Gesondheid Organisasie die genotipiese MTBDRplus toets vir die 
diagnose van Tuberkulose en middel-weerstandige Tuberkulose onderskryf. Hierdie toets word 
tans op groot skaal in Suid Afrika gebruik. Dit kan egter wees dat genotipiese toetse baie meer 
probleme kan he as wat aanvanklik verwag is. Die HIV pandemie gaan toenemend gepaard met n 
toename van nie-tuberkulose mycobacteria. Die sensitiwiteit van genotipiese toetse op monsters 
met onderliggende nie-tuberkulose mikobakteriese spesies vereis dus verdere evaluasie. Die doel 
van hierdie studie was ook om die betroubaarheid van die MTBDRplus-toets te bepaal vir die 
opsporing van middelweerstandige TB waar die nie-tuberkulose backteriële lading hoog is. DNA 
van kliniese relevante nie-tuberkulose mikobakteria en  multi-middelweerstige TB isolate was 
bekom. Verskillende verdunnigs van die spesifieke NTM DNA te same met die van MDR-TB 
DNA is gemaak en onderwerp aan die MTBDRplus toets. Bekende gemengde NTM- en TB 
geïnfekteerde kliniese isolate en sputum sedimente was ook geevalueer vir die opsporing van TB 
en middel weerstandigheid met die MTBDRplus toets. Hierdie studie verskaf bewyse dat die 
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MTBDRplus toets nie betroubaar is met die diagnose van sensitiewe- en middel weerstandige 
Tuberkulose in monsters met onderliggende nie-tuberkulose mycobacteria nie.  
 
 
Verskillende verdunnings van gesuiwerde DNA van MDR en pan-sensitiewe TB isolate is 
gemaak om die sensitiwiteit van die MTBDRplus toets vir die opsporing van 
middelweerstandigheid te bepaal. Die MDRDRplus toets is gebruik met hierdie verdunnings. 
Resultate in hierdie studie toon dat die MTBDRplus toets effektief is met die identifisering van 
wilde-tipe DNA (dit beteken middel sensitief) in gene wat geassosieer word met middel 
weerstandigheid gedurende die vroeë ontwikkeling van weerstandigheid. Hier teenoor toon die 
resultate dat in die later stadium tydens behandeling, wanneer beide die wilde-tipe (sensitief) en 
mutante DNA (weerstandig) teenwoordig is, is die opsporingslimiet vir die mutante DNA maar 
1:55. As gevolg van hierdie resultate raai ons aan dat die MTBDRplus toets nog verder verbeter 
moet word of dat ander toetse ontwikkel moet word om hierdie beperkinge aan te spreek. 
 
 
 Amplikon kruiskontaminasie kan n groot impak hê op die betroubaarheid van enige genotipiese 
diagnostiese toets. Die finale stappe van MTBDRplus toets behels die gebruik van 'n oop sisteem 
sodat kontaminasie maklik kan plaasvind. In die 4de doewit 'n konsep vir 'n patenteerbare 
geslotebuis toestel ontwikkel en die resultate het getoon dat kontaminasie suksesvol uitgeskakel 
kan word. Hierdie toestel kan verbeter na 'n outomatiese apparaat verbeter word sodat die 
module genotipering van verskeie monsters moontlik kan maak.  
 
 
Die resultate van hierdie studie beklemtoon die noodsaaklikheid van 'n sensitiewe goedkoop 
“point of care” diagnostiese toets wat nie intensiewe opleiding benodig nie. 
 
 
. 
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CHAPTER 1 
1. Introduction 
 
1.1. Background 
The World Health Organization (WHO), in an initiative for effective Tuberculosis (TB) /Multi-
drug resistant TB (MDR-TB) control, developed and adapted the directly observed treatment, 
short course (DOTS) scheme (8). The main priority of the DOTS was to prevent the emergence 
of drug-resistant TB through high cure rates of drug susceptible TB. However, as this strategy 
did not aim at accelerating early detection and subsequent treatment of drug resistant patients, 
spread and resurgence of drug resistant TB occurred. In recognition of the deadly threat of 
virtually untreatable TB, the DOTS is now enforced by the WHO to implement rapid drug 
resistant TB testing by culture coupled with commercially available line probe systems in 
countries with a high TB burden (12).  
 
In 2006, after 12 years of the DOTS implementation, South Africa‟s (SA) cure rate for new 
smear confirmed cases, re-treatment cases was 74% and 67% respectively, far below the WHO 
target of 85% (10). With over 14,000 cases of MDR-TB estimated in 2007 to occur annually, 
South Africa ranks among the top ten countries in the world for drug resistant TB (11).  
 
Mathematical modelling demonstrates that continuance with the current TB control strategies 
will exacerbate transmission of TB and drug resistance (7) and that implementation of culture 
and drug susceptibility testing (DST) on 37% of new TB cases and 85% of retreatment cases will 
save approximately 50,000 lives, preventing nearly 8000 (14%) MDR-TB cases. However, the 
model also estimates that there would be no impact on incidence of extensive drug resistant 
(XDR)-TB (3). A subsequent study also suggests that case detection targets above 70% must be 
pursued if eradication of TB is to be attained. This may be achieved by increasing diagnosis of 
TB through active rather than passive case finding and utilizing rapid and highly sensitive 
techniques such as molecular line probe assays (2). 
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The WHO now recognizes that among response priorities, rapid detection of anti-TB drug 
resistance, through integration of molecular assays into routine laboratory logarithms as well as 
monitoring of drug resistance especially MDR/XDR-TB in new patients and its transmission is 
of paramount importance to curb the disease (11). 
 
1.2. Problem Statement 
In 2008 the WHO issued a call for accelerated use of a commercially available PCR based 
MTBDRplus test for detection of isoniazid and/or rifampicin resistant M. tuberculosis from 
smear positive sputum cultures (9). Two tests, the Inno-lipa and the MTBDRplus assay were 
recommended. Evaluation of the genotype MTBDRplus test showed a high correlation with 
routine culture based DST (1). The MTBDRplus test is now widely implemented in SA for 
detection of drug resistant TB. However, successful implementation of this methodology 
requires a change in the way in which M. tuberculosis is inactivated in sputum samples. Prior to 
microscopy, sputum specimens are currently treated with sodium hypochlorite (NaOCl) to 
increase the sensitivity of detection of M. tuberculosis by microscopy (4,6). This pre-treatment 
step also sterilizes the specimen and thereby making it safer for laboratory technicians. However, 
NaOCl compromises mycobacterial deoxyribonucleic acid (DNA) integrity thereby inhibiting 
subsequent PCR amplification. This suggests that polymerase chain reaction (PCR) based 
MTBDRplus test cannot be performed directly on NaOCl inactivated sputum specimens. Thus an 
alternative method which will allow sterilization of sputum specimen without compromising 
mycobacterium cell wall integrity for microscopic detection and genomic DNA such that PCR-
based drug resistance genotyping can be performed directly on sputum specimens will enable 
early detection of TB and drug resistant TB. Furthermore, there is a close association between 
TB and HIV and many immune compromised patients (such as HIV sero-positive patients) can 
be infected with non-tuberculous mycobacterium (NTM) (5). Due to the growing HIV epidemic, 
it is not known whether the presence of NTM‟s in sputum specimens influence the detection of 
drug resistant TB by the MTBDRplus test.  
 
1.3. Hypothesis 
In this study we hypothesize that an alternative method which will provide a safe sterile 
concentrated specimen without compromising mycobacterial stainability, genomic DNA 
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integrity and PCR amplification for genotypic drug DST would significantly improve diagnosis 
of TB and drug resistant TB. We also hypothesize that a single tube enclosed line probe system 
will prevent contamination and that the MTBDRplus assay will not be able to detect underlying 
drug resistant TB in sputum samples where NTM bacterial load is high.  
 
1.4. Aims 
To improve the MTBDRplus assay for genotypic drug resistance testing of M. tuberculosis and 
evaluate the influence of NTM‟s and hetero-resistance on the performance of this test.  
 
Specific aims 
 To develop methods: 
o which will not compromise the ability of inactivated mycobacterium to stain with 
auramine-O and genomic DNA integrity for PCR amplification. 
 To determine the influence of the presence of NTM‟s on the detection of drug resistant 
TB. 
 To determine the limit of detection of drug resistant M. tuberculosis in hetero-resistant 
isolates.  
 To develop a single tube closed line probe system which will prevent contamination 
 
These aims will be discussed separately as different projects: 
1.1 Sputum processing 
1.2 Influence of NTM‟s on drug resistance testing 
1.3 Hetero-resistance 
1.4 Development of a closed line probe assay system 
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CHAPTER 2 
2. Literature review 
Current methods for drug resistance testing of Mycobacterium tuberculosis 
2.1. Introduction 
Mycobacterium tuberculosis, the bacilli that causes Tuberculosis (TB) remains one of the three 
deadliest infectious pathogens worldwide despite rigorous attempts to control the epidemic by 
National TB Control programs under the guidance of World Health Organization (WHO) (241). 
Surveillance data suggest that interplay of several dynamics work in synergy to aggravate 
acquisition and transmission within communities fuelling the TB epidemic. These include; 1] 
emergence of multi-drug resistance (MDR) and extensive drug resistance (XDR) TB strains, 2] 
Human Immunodeficiency Virus (HIV) (3,18,44,68), 3] lack of systemic monitoring of TB 
cases, 4] delay in diagnosis of new cases and defaulters and 5] inappropriate therapy due to poor 
treatment adherence or inadequate drug therapy (9,18,62). In 2006, the TB incidence rate in 
South Africa (SA) was estimated by the WHO to exceed 900/100 000 population per year (238) 
with more than 6000 new MDR-TB cases detected each year. In 2008, this number escalated to 
about 13000 MDR-TB cases per year (240,241). Approximately 9.6% MDR-TB, 10.5% XDR-
TB cases with 14.2% fluoroquinolone resistance in SA was reported by the WHO in the fourth 
world drug resistance surveillance (240).  
 
Drug resistance in SA was extensively highlighted by the KwaZulu Natal province outbreak 
where 72 patients were diagnosed with MDR-TB, of which 53 had XDR-TB (68). The causal 
strain, F15/LAM4/KZN was found to have been responsible for cases of MDR-TB since 1994 
and XDR-TB from 2001 (170). Subsequently it has been shown that other drug resistant TB 
strains are widespread in the country (144). Outbreaks of MDR-TB have been described in the 
Eastern Cape [Atypical Beijing] (206), the gold mines [LAM4] (33) and in the Western Cape 
[Beijing/W-like (95)], [Low Copy Clade (LCC) (228)], [F11] and [F28] (207). The MDR-TB 
outbreaks in Western Cape are driven by specific strain lineages, the Beijing R220 cluster and 
the LCC DRF150 strain (207). These strains are highly transmissible irrespective of the presence 
of characteristic drug resistance causing mutations (119). It is estimated that the incidence of 
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drug resistant TB cases in the Western Cape will double by 2.4 every 8 years. The main driving 
force of this phenomenon is the increase in cases caused by the Beijing strain R220 (228). 
 
Prior to the 1940‟s, TB drug resistance was thought to emerge only as a result of treatment 
relapse or inadequate drug therapy, that reactivation of latent infection explained development of 
disease rather than disease transmission (224). Since the 1950‟s, it has also been thought that 
drug resistance strains are less virulent and less transmissible, however recent reports provide 
evidence that drug resistant strains can develop compensatory mutations which restore fitness 
(33). Certain drug-resistance mutations have also been shown to incur a very low or no fitness 
cost (23,24). This suggests that outbreak strains have unique properties which aid in increased 
transmissibility and drug tolerance, however the influence of HIV cannot be excluded (119). 
Emerging evidence also suggests that the exponential increase over time of the Beijing lineage 
may be a reflection of enhanced pathogenicity rather than transmissibility (95). 
 
Members of the same bacterial population can independently acquire distinct drug resistance 
mutations, suggesting that multiple strains can co-exist within a patient with different 
susceptibility and fitness profiles (209). This phenomenon is defined as hetero-resistance. 
Hetero-resistance further complicates diagnostic or treatment outcomes as the one strain can 
become predominant masking the presence and therefore detection of the other strain (177,235). 
It is therefore important to establish techniques to rapidly and accurately detect drug susceptible 
and drug resistant TB.  
 
2.2. Detection of TB by microscopy 
Conventional light microscopy remains the primary method for diagnosing pulmonary TB in 
developing countries regardless of its various limitations (130). These include factors such as 1] 
its value only in areas with high TB incidence or prevalence where patients are diagnosed with 
high bacterial loads in sputum (5,000-10,000 bacilli.mL-1) (37), 2] its relatively low sensitivity 
(20-80%) in extra-pulmonary TB and TB/HIV co-infected patients when compared to traditional 
culture methods (77,102) and 3] the lack of specificity for M. tuberculosis. The problem of the 
low specificity of smear microscopy has only recently received attention as a result of frequent 
detection of opportunistic non-tuberculosis mycobacteria (NTM‟s) in HIV co-infected 
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individuals (54,139,167,231,233). Detection and diagnosis of NTM‟s has become particularly 
important as clinical manifestations of some NTM disease can be indistinguishable from those of 
TB (46,47). Cases where NTM disease/isolation was misdiagnosed as TB or co-infection with 
NTM was missed (154) and due to inadequate treatment administration classification of cases as 
MDR-TB has been documented in resource-limited settings (45,48,101,214). Another major 
disadvantage of smear microscopy is its limited value for diagnosis in paediatric cases as it is 
often difficult to get a good quality sputum in sufficient quantities in children (99,152,201).  
 
2.3. Fluorescent light emitting diode (LED) microscopy  
Fluorescence microscopy has not gained access to routine diagnostic laboratories in most 
developing countries despite its higher sensitivity (~10% higher) compared to smear microscopy 
(37). The cost for routine maintenance as well as running costs (electricity and requirement of 
specialized mercury vapour light sources) makes fluorescence microscopy less favourable than 
smear microscopy (140). Several light emitting diode microscopes (LED) which also use 
fluorescence have been developed (2,140) and recommended to replace fluorescence 
microscopes and to serve as an alternative to smear microscopy. These microscopes are robust, 
inexpensive, do not consume too much electricity (124) are portable and can run on batteries 
(107,140) compared to mercury vapour lights used on fluorescent microscopes. LED 
microscopes can also be used to view slides at higher magnification (2) and have been shown to 
reduce time of AFB detection when compared to fluorescence microscopy and are more sensitive 
than smear microscopy (114,220). Studies evaluating the impact of the implementation of LED 
microscopes on diagnosis and treatment at point of care sites, as well as combining LED 
microscopy with novel approaches for early TB and drug resistance case detection are however 
still required.  
 
Decontamination methods 
Strategies to enhance sensitivity of smear microscopy have been assessed. These involve 
thinning, decontamination and centrifugation of specimens to concentrate bacilli. Numerous 
decontaminants and digestive reagents such as cetylpyridinium bromide (CPB), cetylpyridium 
chloride (CDC) have been suggested (239). However N-acetyl-L-cysteine sodium hydroxide 
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(NALC/NaOH) is the most frequently used decontaminant for respiratory specimen prior to 
microscopy and mycobacterial cultivation (26,239).  
 
Sterilization of respiratory specimens with sodium hypochlorite (NaOCl) prior to microscopy has 
also been suggested to be an alternative method to concentrate and provide a relatively safe 
specimen which is non-infectious to laboratory technicians (80). No significant increase in the 
sensitivity of microscopy subsequent to decontamination with NALC-NaOH and or NaOCl 
treatment followed by concentration with centrifugation was indicated (10,36,37). High 
sensitivities were however reported in clinical specimens from a TB/HIV endemic population on 
specimens processed with NaOH/NaOCl. NaOCl has gained favour in routine microscopic 
diagnosis in some laboratories as a useful sedimentation agent (80,173).  
 
2.4. Drug resistance detection 
Numerous phenotypic and genotypic methods have been described for DST and only a few are 
frequently used. Although genotypic methods offer several advantages over culture techniques 
such as reliability, reproducibility, and a short turnaround time (TAT) for results which may 
potentially help improve patient management (18), DST by culture remains the mainstay to 
detect drug resistance. Genotypic methods have become particularly important as they enable 
determination of the specific gene(s) and mutation(s) causing resistance (86) and coupled with 
phenotypic methods allow determination of resistance (59,204). This chapter will review the 
currently available phenotypic and genotypic methods for detection of drug resistance. 
 
2.4.1. Phenotypic methods 
One of the most important characteristics of culture based methods is that they take advantage of 
the critical drug concentration which discriminates drug resistant and susceptible strains. The 
critical concentration is defined as the drug concentration which completely inhibits growth of 
actively dividing drug susceptible mycobacteria (34). Table 2.1 summarizes the critical 
concentrations of drugs in different media which form part of treatment regimens frequently used 
for the treatment of drug susceptible and resistant TB (239).  
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2.4.1.1. Solid Medium Based Methods  
Four egg or agar based solid culture methods are proposed by the WHO for DST: these are the 
proportion, resistance ratio, absolute concentration and the micro-dilution method (237). With 
the proportion method, the minimum inhibitory concentration (MIC) is defined as the drug 
concentration where <20 colonies (equivalent to 1% critical proportion) form while confluent 
growth is observed in the drug free media (34). The MIC in the agar dilution method on 
Middlebrook 7H10 medium is defined as the drug concentration on which fewer colonies were 
found when compared with the 10-4 quadrant together with a confluent growth on the 10-2 drug-
free quadrants. The laboratory strain, H37Rv is included as an internal control to adjust for batch 
to batch variation of medium on both methods. The absolute concentration method is similar to 
the resistance ratio method; serial dilutions of carefully controlled inoculums containing 2 x 103 
to 1 x104 CFU of mycobacteria are made (34). These dilutions are then inoculated in media with 
and without the drug. Resistance is defined as growth that is greater than a certain number of 
CFU‟s (usually 20) at a particular drug concentration. In these methods, for a resistant isolate the 
calculated proportion is higher and for a susceptible strain the calculated proportion is lower than 
the critical proportion (34,237). The proportion method on Lowenstein-Jensen (LJ) is used 
worldwide as a reference method as DST critical concentrations for both 1st and 2nd line drugs 
have been well validated on this media (Table 2.1) (239). A disadvantage of these traditional 
culture methods is that they take about 4-6 weeks before resistance or susceptibility is confirmed 
and have limited sensitivity, despite evidence of high specificity (138). Inaccurate or false 
negative phenotypic results which may result in inappropriate treatment of patients leading to TB 
related mortalities (176) and the current drug resistant epidemic have also been reported (69).  
In-house solid medium based culture techniques have been proposed in an attempt to reduce the 
time for DST results. These include the E-test, nitrate reductase assay (NRA), thin layer agar 
(TLA) assay as well as mycobacteriophage based assays.  
 
The E-test  
The E-test (AB Biodisk, Solna, Sweden) is a commercial system which detects drug resistance 
on a plastic strip impregnated with a gradient of the antibiotic. This antibiotic gradient also 
allows determination of the MIC on the surface of 7H11 agar plates supplemented with OADC. 
The MIC is defined as the drug concentration at which growth of actively metabolizing 
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mycobacteria is inhibited. An inoculum equivalent to 3.0 McFarland is recommended with the 
results available within 5-10 days. Evaluation studies show correlation when the method is tested 
against the LJ proportion method for the four 1st line drugs (3,64,65,153). A recent study in 
Uganda for rifampicin (RIF) resistance showed complete agreement between the E-test and the 
direct BACTEC method when compared to the indirect (DST subsequent to mycobacterial 
culture) BACTEC 460 assay (162). The E-test system is however criticized for the substantial 
number of false negatives and positives (Table 2.2) (64,76) although two other subsequent 
studies reported high specificities and sensitivities (3,162). Further evaluation studies are needed 
for this test. 
 
The nitrate reductase assay 
The nitrate reductase assay (NRA), is based on the ability of viable M. tuberculosis to reduce 
nitrate to nitrite in standard LJ or modified Middlebrook 7H9 medium incorporated with 100 
mg/L of potassium nitrate (KNO3) (155). Reduction to nitrite causes a reddish/violet colour 
change on the surface of slants on addition of the Griess reagent (11,171). Clinical specimens or 
cultured isolates are inoculated in the presence and absence of the drug. Adaptation of NRA 
method for DST directly on clinical specimens has the advantage of reducing the time for 
availability of results in comparison to the indirect method and has been shown to yield reliable 
results with high sensitivities for Isoniazid (INH) and Rifampicin (RIF) (230). Pyrazinamide 
(PZA) resistance detection by the NRA assay with the drug‟s analogue nicotinamide which also 
possesses an anti-tuberculocidal activity has also been described (126). Both PZA and 
nicotinamide are pro-drugs that are catalyzed by the enzyme pyrazinamidase/nicotinamidase to 
pyrazinoic acid (POA) and nicotinic acid (246,247). Nicotinamide unlike PZA which requires an 
acidic pH works well at a neutral pH and a critical concentration of 250 mg/L produced 
comparative results to the BACTEC 460 system (126) (Table 2.2). Among other limitations, 
DST for streptomycin (SM) and ethambutol (EMB) has however been reported to be less reliable 
with low sensitivities and specificities (Table 2.2). The low sensitivity and specificity to these 
two drugs may be explained by the presence of hetero-resistant isolates (213) or faster 
deterioration of the drugs in the media (143).  
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Thin layer agar assay 
The thin layer agar (TLA) assay also known as the microcolony method is based on inoculation 
of an M. tuberculosis suspension on either Middlebrook 7H10 or 7H11 TLA and visualization of 
microcolonies under a microscope (10X magnification) (192). The TLA assay has been 
evaluated for the four 1st line drugs (INH, RIF, EMB and SM) and for ofloxacin (OFL) and 
kanamycin (KAN) with reliable results (127,180,192) (Table 2.2). The assay is inexpensive, 
simple to perform and the results are available faster in comparison to traditional solid medium 
based assays but slower than with the BACTEC systems. Rigorous safety conditions are however 
necessary (180) (Table 2.2). MDR-TB can be detected within 13 days on smear positive sputum 
and within 38 days in smear negative sputa (127). Lower contamination rates in comparison to 
the BACTEC MGIT 960 system, proportion method and the microscopic-observation drug-
susceptibility (MODS) assay were reported (Table 2.2).  
 
2.4.1.2. Mycobacteriophage based methods for DST  
Two rapid Mycobacteriophage based assays on solid media for M. tuberculosis DST were 
proposed. The one phage assay is based on Mycobacteriophage replication within M. 
tuberculosis; replication of phage is then determined by counting viral particles on fast-growing 
M. smegmatis after overnight incubation. Growth is indicated by clear plaques which form a 
turbid lawn on M. smegmatis (244). The luciferase reporter format however relies on production 
of light by recombinant phages on infection into mycobacteria. The recombinant phage contains 
a luciferase gene which once within viable mycobacteria causes oxidation of luciferin to 
oxyluciferin and subsequent light emission. Activity of the gene and therefore presence of viable 
mycobacteria is determined by luminescence in the presence or absence of antibiotics (90). Both 
formats are based on the replication of phage such as D29, TM4, L5 and Chel2 (16,108,166,187) 
inside viable mycobacteria.  
 
The FastPlaque response assay also known as the FastPlaque TBTM-MDRi (Biotech 
Laboratories ltd, Ipswich, UK) is a commercially available Mycobacteriophage replication assay 
and can be used to detect RIF resistance directly from clinical specimens (7). Decontaminated 
clinical specimens are inoculated in the presence or absence of RIF then in a suspension of 
phages. After sufficient time has elapsed to allow the mycobacteria to take up the phage, the 
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remaining extracellular phages not infecting the M. tuberculosis are removed with a virucidal 
solution. The replicating phages are visualized within 2 days as plaques or lysis when plated in 
non-pathogenic mycobacterium such as M. smegmatis. Presence of viable M. tuberculosis in the 
presence of RIF is interpreted as drug resistance to this drug. A major limitation of phage based 
assays include the generation of inconsistent results in numerous studies (6,7,30,42,66,145,198).  
 
The Luciferase reporter phage assay is a high throughput screening micro-plate bacteriophage 
assay (66). The assay was shown to be highly sensitive and specific for detection of RIF 
resistance even in an isolate which did not possess mutations in the 81bp region of the rpoB gene 
suggesting that it could be more sensitive than methods which are limited to the analysis of the 
hot spot region of the rpoB gene (16,17).  
 
Among limitations of phage based assays, the lack of specificity of Mycobacteriophage for M. 
tuberculosis, lack of evaluation studies for drug resistance other than RIF, and its inconvenience 
in testing a large number of isolates are central (Table 2.2). Phage based assays have also been 
shown to have a TAT and cost comparative to that most molecular based techniques.  
 
Although the E-test, NRA, TLA and Mycobacteriophage based methods are cheaper, they often 
are not as simple to perform and require high standards of biosafety and quality control (Table 
2.2). 
 
2.4.2. Liquid Based Methods 
Numerous liquid culture-based DST methods have been introduced in the past years. Many of 
these assays are commercially available and rely on the principle that M. tuberculosis grows 
faster in liquid than on solid media. Some of the techniques are manual and require interpretation 
of results by eye while others are automated.  
 
BACTEC systems  
BACTEC system (Becton Dickinson, Franklin Lake, N.J.), the first manual liquid based culture 
method introduced in the 1970‟s, utilizes modified 7H9 or 7H12 Middlebrook broth containing a 
14C labelled radioactive palmitic acid substrate (196). Growing mycobacteria metabolize palmitic 
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acid releasing radioactive 14CO2. The amount of radioactive 14CO2 released is translated into a 
numerical value designated as the growth index (GI), a GI value higher than 10 is considered as 
positive (196). The first evaluation on the rapid radiometric DST of M. tuberculosis was 
conducted in 1981 (196,200). A subsequent study reported overall agreement of radiometric 
results with those obtained by the proportion method with specificities, sensitivities higher than 
those stated in an earlier study. The BACTEC 460 system has since been the leading rapid 
culture system for M. tuberculosis for the past two decades and provides DST within 4-12 days 
(69,186,189,200,218). Critical concentrations for both 1st and 2nd line drugs have been validated 
on this system (Table 2.1). The BACTEC 460 system is also the reference method for DST for 
PZA resistance as a BACTEC 460 vial is available which provides the necessary acidic medium 
(pH 5.9) for the activity of the enzyme (92).  
 
The BacT/Alert 3D system  
Another addition to the BACTEC system is the BacT/Alert 3D system formerly known as the 
MB/BacT system (bioMireux, Durham, N.C). It is an automated commercial liquid culture-based 
system that measures microbial growth every 10 minutes (188). The system uses a modified 7H9 
Middlebrook broth containing a pH indicator mixture and incorporates a colometric sensor at the 
bottom of the vial which measures changes in CO2 production by the metabolizing mycobacteria. 
Elevated CO2 concentrations lower the pH of the medium which in turn produces a colour 
change in the sensor which is detected by the reflectometric unit of the instrument (236). Change 
in colour from green to yellow indicates a positive reaction and each vial is continuously 
monitored inside the apparatus (12,169). Evaluation studies show concordance with reference 
methods with comparable sensitivities and specificities (Table 2.2).  
 
The BACTEC Mycobacteria Growth Indicator Tube (MGIT) 960 system 
The BACTEC MGIT 960 (Becton Dickinson Microbiology Systems, Sparks, MD) is an 
automated version of the MGIT system. The systems are based on an oxygen-quenching 
fluorescence sensor embedded at the bottom of the tube containing enriched Middlebrook 7H9 
broth. On the BACTEC MGIT 960 system incubation and reading of fluorescence emitted occurs 
continuously inside the machine using a predefined algorithm to interpret the fluorescent signal 
and gives results as either negative or positive (190). Recently included in the BACTEC MGIT 
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960 system is the MGIT 960 PZA kit containing tubes with modified 7H9 broth which enhances 
growth of mycobacteria at pH 5.9 which enables detection of PZA resistance (92). In DST, the 
BACTEC MGIT 960 system interprets the results as susceptible or resistant to the antibiotic 
under investigation with results available in 8 days. Although this system is used more regularly 
than the BACTEC TB-460 it poses more danger to laboratory personnel and requires special 
disposal systems. The BACTEC MGIT 960 system however is reported to be more prone to 
contamination than in the BACTEC 460 system (Table 2.2) (242). The performance of the 
BACTEC MGIT 960 system has also not been shown to be superior to that of the BACTEC 460 
system (242). 
 
Recently, the focus has shifted to rapid and affordable direct tests in which clinical specimens are 
directly inoculated in drug-free and drug containing medium (41,74) or amplified for detection of 
drug resistant-TB (79,104). These assays include the MODS assay, microplate alamar blue assay 
(MABA), tetrazolium microplate assay (TEMA), resazurin microplate assay (REMA) 
(53,147,164) and the ESP II system (110).  
 
Microscopic Observation Drug Susceptibility assay (MODS)  
MODS is an „in-house‟ assay which enables DST by detection of early growth of M tuberculosis 
as „strings and tangles‟ of bacterial cells in 7H9 Middlebrook medium (38). The inoculation is 
performed on 24-well plates with or without antibiotics at 37°C (149). The assay has numerous 
features which make it suitable for use in resource poor settings; however several aspects also 
limit its application in these settings (Table 2.2). MODS is not superior to any liquid culture 
based assay and is also prone to contamination in comparison to other liquid culture systems 
which necessitates repeated or rigorous decontamination of specimens (57,60,70,150).  
 
The versa TREK system  
Previously known as the ESP culture system ΙΙ (Trek Diagnostic systems, West Lake, OH) this 
non-radiometric automated method can be used for detection and DST of M. tuberculosis. This 
system along with the BACTEC 460 was the first two broth systems accepted by the Food and 
Drug Administration for DST. Using an enriched 7H9 broth, the assay detects mycobacterial 
growth by measuring gas pressure changes inside culture vials caused by mycobacterial 
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metabolism. The ESP II system can rapidly detect drug resistance to INH and RIF but 
discrepancies between the system and BACTEC 460 for STR and EMB were observed (20,182). 
PZA resistance with the BACTEC 460 system as the reference was in concordance (110). No 
evaluation studies have yet been published for performance of this assay directly on clinical 
specimens. 
 
Colometric microplate liquid medium based assays 
Colometric in-house assays were developed with the aim to overcome the high cost of 
commercially available techniques (164). These methods rely on colour changes which are 
observed by eye resulting from oxidation-reduction (redox) reactions. The redox reactions occur 
between an indicator and O2, CO2, NO3 or drug metabolism in culture medium when M. 
tuberculosis is grown in the presence or absence of an antibiotic. These assays include, methods 
such as the MABA, TEMA and the REMA (128,158,164,175). The alamar blue, 4, 5-
dimethlythiazol-2yl)-2, 5-diphenyl tetrazolium bromide (MTT) and resazurin are used as 
indicator dyes for MABA, TEMA and REMA assays respectively (116,142,147). 
 
TEMA and MABA have been shown to be highly sensitive and specific for detection of 1st line 
drugs (Table 2.2) (115,147). Discordances for SM and especially EMB have been reported. 
These discrepancies have been attributed to differences in the media of the respective assays or 
degree of degradation of the respective drugs in the media (136). DST for 1st line drugs as well 
as PZA resistance with nicotinamide has also been determined on the REMA assay (129) (Table 
2.2). Nicotinamide at the critical concentration of 250 mg/L on REMA assay produced 
comparative results to the BACTEC 460 system (129). As colour change can be detected 
visually, no additional devices are necessary and growth can be detected earlier before colonies 
become visible (147). REMA is more cost effective compared to MABA and TEMA as resazurin 
(the main component of alamar blue) is less expensive than alamar blue or MTT (142,147). 
Although these colometric assays are cost effective, rapid and also allow MIC determination, 
low sensitivity and specificity for EMB, STR and capreomycin (CAP) is documented (Table 
2.2). The need for rigorous safety conditions for lab personnel may also limit their use in 
resource limited countries.  
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2.4.3. Drug resistance genotyping 
Genotypic methods for DST are based on evidence that acquisition of drug resistance mutations 
in M. tuberculosis occur by chance as a result of imperfect chromosomal replication. Bacteria 
with drug resistance mutations are positively selected during periods of discontinuous drug 
therapy (e.g. through non-compliance or inappropriate therapy) (94). Resistance causing 
mutations occur mainly in regions targeted by antibiotics, in enzymes which activate or 
deactivate certain essential genes or on the promoter regions upstream of these genes. Resistant 
bacteria which do not have classical drug resistance mutations suggest unknown mechanism(s) 
are involved (94,248). This is also supported by the differences observed in MIC‟s of strains 
harboring the same mutation (87,94,122). 
 
The mutation rate on the M. tuberculosis genome as determined using the Luria-Delbrûk 
fluctuation analysis demonstrates that in vitro INH-resistance emerges at a rate of 3.5 x 10-6 and 
RIF resistance at a rate of 3.1 x 10-8 mutations per cell division (55). DNA sequencing has shown 
that 95-98% of RIF-resistant isolates are also resistant to INH, making RIF-resistance a good 
predictor for MDR-TB (156). More than 90% of M. tuberculosis strains phenotypically resistant 
to both RIF and INH respectively were also shown to harbor point mutations within the 81bp-hot 
spot region of the rpoB gene (codon 507-533). As a result of these findings, detection of RIF 
resistance conferring mutations within this region forms the foundation for the detection of 
MDR-TB. More recently, due to the resurgence of XDR-TB, evidence of INH (197) and RIF 
mono-resistance (207), multiplex PCR assays which incorporate classical mutations causing 
resistance to both 1st and 2nd line TB drugs have been developed (86). Prior to genotypic drug 
resistance testing, smear positive sputum specimens are decontaminated followed by 
mycobacterial cultivation or direct genotyping on sediments. The decontamination step is crucial 
as it sterilizes the specimen and increases mycobacterial detection. 
 
2.4.3.1. Preparation of samples prior to PCR amplification 
The standard protocol for preparation of clinical specimens prior to PCR amplification involves 
digestion and decontamination of specimens with NALC-NaOH (61). DNA extraction methods 
by commercial kits, proteinase K phenol-chloroform purification method, carboxypropylbetaine 
(CB-18) coupled with glass beads homogenation have also been explored (50,100,212,234). 
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Although these techniques provide purified DNA, multiple steps which are time consuming, 
labour intensive and expensive are involved (212). The boiling method which involves 
mycobacterial cell lysis for 5 minutes at 100ºC to release crude DNA and reduce PCR inhibitors 
is a simple, cost effective and rapid method which has been shown to yield sufficient DNA for 
PCR (212,217).  
 
Bactericidal reagents which sterilize and simultaneously lyse mycobacterial cells have not yet 
been explored for PCR based diagnostic techniques. There are commercial kits which use 
bactericidal reagents coupled with PCR based assays, however the bactericides in these kits are 
not mentioned (15). Limited data is available on the efficiency of bactericidal reagents against 
mycobacterial species. Literature reviews focus on bactericides against a variety of microbial 
organisms but not specifically on M. tuberculosis. The most frequently used bactericides are 
aldehyde based sterilizing reagents such as glutaraldehyde (GTA), NaOCl and peracitic acid 
(C2H4O3) and are mainly used for sterilization of medical equipments and hospitals (71).  
 
More recently ortho-phthalaldehyde (OPA), an aromatic dialdehyde has been proposed as a 
possible alternative to GTA for high-level disinfection (211). It was shown that 0.5% w/v OPA 
can rapidly and efficiently sterilize a range of NTM‟s and more importantly GTA-resistant 
mycobacterial strains (211). Although GTA is a more effective cross-linking agent and its own 
uptake may be decreased by virtue of its extensive cross-linking nature to amino acid residues at 
the bacterial cell surface. GTA thus inactivates cells at a slower rate than OPA at the same 
concentration (63). It is suggested that OPA may induce inactivation by cross linking the active 
sites of cysteine to neighbouring lysine residues (199).  
 
NaOCl, with hypochlorous (HOCl) acid as the active moiety, is a powerful bactericidal, 
sporocidal and fungicidal agent which has been demonstrated to be highly effective against M. 
tuberculosis (174). It is relied upon for sterilization of mycobacteria by lysing the mycobacterial 
cell through interactions with amino acid groups and primarily through progressive oxidation of 
disulphide resulting in consequent degradation of DNA within minutes of contact (10). HOCL is 
a potent bactericidal agent which is active at even concentrations below 0.1mg/liter (174). 
Glucoprotamin is non-volatile, water soluble, non-corrosive, non-mutagenic, and easily 
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degradable compound (243). It is bactericidal against mycobacteria, fungi and viruses. It is 
highly active against glutaraldehyde resistant strains of M. chelonae (137).  
 
Peracitic acid, an oxidizing agent effective at low temperatures, decomposes to non toxic 
residues and is effective in the presence of organic matter. The extra oxygen atom is highly 
reactive and interacts with most cellular components and functions to cause cell death. Peracitic 
acid inactivates many different critical cell systems and this is the key to its broad spectrum 
antimicrobial activity even against resistant M. terrae and M. avium (205,221). 
 
A challenge with bactericide sterilization prior to PCR amplification may be however its 
implications on DNA integrity or DNA degradation and possible introduction of sequence 
changes or false positives on genotypic results (15,199). Determination of the time duration for 
the respective bactericide to penetrate the mycobacterial cell wall, efficiently sterilize the clinical 
specimen or culture without causing sequence changes or DNA degradation is critical.  
 
2.4.3.2. Nucleic acid based methods 
Mutations in one or several genes with different mutation frequencies are implicated in the 
acquisition of drug resistance in M. tuberculosis (Table 2.3). Drug susceptible isolates lack these 
corresponding gene mutations and this forms the basis of drug resistance genotyping. The 
inability to detect all mutations conferring resistance remains a major challenge to the successful 
development of highly sensitive genotypic DST methods. The main reason for this is that the 
mechanisms of drug resistance to some of the drugs are not fully understood (94). Different 
geographic regions with different prevalence rates of mutations in the drug resistance conferring 
genes have been documented and this further complicates the development of these techniques 
(39,98,184). Region specific mutation screening methods are not yet in place and this may lead 
to misdiagnosis of drug resistance. Many of these methods are also complicated by the need for 
downstream processing to enable the detection of genotypes within the amplified PCR product. 
The complexity and multiple steps of these techniques greatly increase the risk of cross-
contamination and thereby misdiagnosis.  
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Single Strand Conformational Polymorphism (SSCP), Restriction Fragment Length 
Polymorphism (RFLP), allelic Amplification refractory mutation system (ARMS)-PCR, 
heteroduplex analysis (HA), pyrosequencing (84) and probe based hybridization methods such 
dot blot analysis (227) have been described. However, RFLP-PCR based DST has limited use as 
not all mutations conferring drug resistance results in gain or loss of restriction enzyme cutting 
sites (229). ARMS, HA and SSCP-PCR (97) are technically challenging, time consuming with 
limited sensitivity due to high G-C rich regions in mycobacterial genomes which may influence 
mobility shifts of DNA sequences (157). Pyrosequencing, an alternative sequencing method to 
direct DNA sequencing is a rapid high throughput technique that relies on real time detection of 
pyrophosphates (PPi) (89). In contrast to standard sequencing, pyrosequencing does not make 
use of fluorochromes, radioactivity or need post-reaction processing of PCR-products. 
Pyrosequencing approach that combines automated real-time (RT) PCR amplification with 
pyrosequencing has been devised for detection of drug resistance to INH, RIF and 
fluoroquinolones (27,75). Although pyrosequencing is high throughput similarly to standard 
sequencing, it is also cumbersome, costly and technically challenging.  
 
The most promising in-house and commercially available molecular methods developed to detect 
drug resistant TB will be reviewed in the next few sections.  
 
 
Direct DNA sequencing 
For the last decade, this method has been incorporated into the work flow of a number of clinical 
mycobacteriology laboratories and is the reference method for detection of drug resistance 
mutations (85). It involves amplification of the gene of interest or a specific region associated 
with resistance causing mutations and subsequent sequencing of the amplified product to 
determine the presence or absence of specific mutations (85). Sequencing is not only costly, with 
the need for expensive equipment, but also requires expertise (227). Continued use of PCR-DNA 
sequencing for routine DST is therefore impractical in resource poor settings where cost 
effective, rapid techniques would be more of value (227).  
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2.4.3.3. Hybridization Based Methods 
In these assays, amplified PCR products of genes known to confer drug resistance are reversely 
hybridized to immobilized nitrocellulose membrane bound allele-specific labelled probes 
complementary to the wild type or mutant sequence of the gene. Hybridization can be visualized 
by autoradiography, enhanced chemiluminescence, alkaline phosphatase or other detection 
systems (111,162). These assays include the commercially available INNO-Lipa RIF-TB test, 
MTBDR, MTBDRplus and the newly developed MTBDRsl assay.  
 
There are two commercially available assays recommended by the WHO: the Inno-LiPA Rif.TB 
(Innogenetics, Belgium) and the Genotype MTBDRplus assay (Hain-Lifescience, Nehren, 
Germany). These assays are based on multiplex PCR amplification of nucleic acid segments and 
subsequent reverse hybridization of amplicons onto nitrocellulose membrane with immobilized 
probes specific for M. tuberculosis complex and mutations responsible for drug resistance.  
 
Inno-Lipa Rif.TB  
The Inno-LiPA Rif.TB (Innogenetics, Ghent, Belgium) targets the 16S-23S ribosomal RNA 
(rRNA) spacer region for differentiation of the M. tuberculosis complex and detects mutations 
within the hot spot region (codons 507-533) of the rpoB gene (91,194). A major limitation of this 
technique is that it can only detect RIF resistance (91,162,194,203).  
 
Genotype MTBDRplus assay  
The MTBDR (Hain Lifescience, Nehren, Germany) assay enables simultaneous detection of the 
M. tuberculosis complex, the most common mutations conferring RIF resistance and mutations 
in the katG for INH resistance. The Genotype MTBDRplus, a latter version of the MTBDR 
includes mutations in the promoter region of the inhA gene for INH resistance, which also 
confers cross resistance to ethionamide (ETH) (88,191). Both versions accurately identified RIF 
resistance in 98.7% of the cases, when compared to phenotypic DST (18,81,82). Furthermore, 
the Genotype MTBDRplus reported higher sensitivity for INH resistance (Table 2.4). The 
MTBDRplus assay was reported to perform well with significant readability in clinical 
specimens (160). The assay‟s reliability however can be hampered by presence of rare mutations 
and hetero-resistance in clinical specimens (160). Despite these limitations when performed 
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directly on clinical specimens, the MTBDRplus assay has been shown to be a reliable, 
reproducible line probe PCR-based method which could significantly increase early detection of 
drug resistant TB (18,31,141,160).   
 
MTBDRsl assay 
The MTBDRsl assay (Hain Lifescience, Germany), is the latest version of the MTBDRplus 
assay. It is based on the same principle as the MTBDRplus except that it detects resistance to 2nd 
line drugs; fluoroquinolones, aminoglycosides (amikacin and kanamycin) and the cyclic peptide; 
capreomycin and ETH (104). Three recent studies show sensitivities >75% for aminoglycoside 
and capreomycin resistance detection and even lower sensitivities for EMB resistance (Table 
2.4) (28,83,104). This is currently one of the most promising genotypic assays for rapid detection 
of 2nd line drug resistance. 
 
MLPA assay  
The multiplex ligation-dependent probe amplification (MLPA) assay was initially designed to 
screen copy number changes and CpG methylation changes in human genomic DNA (161,226) 
and characterize bacterial genomes. Due to its high probe capacity (can incorporate ~45 probes), 
this assay was modified to enable simultaneous detection of resistance to RIF, INH, and EMB as 
well as genotype specific mutations in the M. tuberculosis genome for specie identification in a 
single assay (21). The selected drug resistance markers can detect approximately 70-85% RIF, 
65-80% INH and 45-65% EMB resistance (21). M. tuberculosis genotype specific speciation 
with simultaneous drug resistance genotyping may help detect outbreak strains early and may 
provide valuable information for treatment and prevention of TB transmission. No evaluation 
studies in large trials have been performed and this needs attention.  
 
Real- time PCR 
RT-PCR methods which make use of Molecular Beacon (MB), TaqMan minor groove binder 
(MGB) and fluorescence resonance energy transfer (FRET) probes have been described 
(105,181,232,245). The sensitivity and efficiency of MB and TaqMan probe coupled PCR at 
detecting MDR-TB in DNA extracts with mixed ratios of mutant and sensitive sequences was 
determined (245). The detection efficiency was shown to be determined first by the amount of 
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each sequence and then by the ratio of the sequences irrespective of the probe system. The 
presence of a second allele did not influence specificity of the probe system (245). In this study 
FRET probes were unable to produce an amplification signal in mixed sequence specimens 
regardless of the quantity or ratio of the different sequences (245).  
 
Cepheid GeneXpert MTB/RIF assay  
The Cepheid GeneXpert MTB/RIF (Sunnyvale, CA) assay a MB RT-PCR based assay has 
recently been described for detection of RIF resistance (79). This assay is an enclosed, fully 
automated system which processes, extracts, purifies and amplifies target sequences directly 
from clinical specimens. The Cepheid GeneXpert MTB/RIF assay makes use of a single use 
sample-processing cartridge system with the GeneXpert instrument which has an integrated 
multicolour real-time PCR detection capacity (79,222). It is the first assay which incorporates 
sample processing, amplification and nucleic acid analysis in one tool (183,222). The assay 
makes use of 6 MB probes with their respective fluorescent dyes and quenchers for detection of 
RIF resistance conferring mutations and has been shown to be highly sensitive and specific even 
on smear negative specimens (26,79). It has also been shown to detect M. tuberculosis H37Rv in 
sputum specimens with mixed NTM species. The GeneXpert has several demonstrated 
advantages such as its large dynamic range, high specificity and on site diagnosis of MDR-TB 
while patients wait (79). The authors showed that the amount of aerosols produced are 
comparative to those generated during smear microscopy and pose insignificant threat to 
laboratory personnel (15). The sterilizing reagent was reported not to influence the sensitivity of 
the assay after 3 hours of exposure, however RIF false positive results were reported (15). 
Although expensive, the GeneXpert MTB/RIF assay is by far one of the most promising recent 
genotypic tools introduced for DST. Further evaluation of this assay for simplicity, robustness 
and accuracy for immediate DST performance in health care facilities to enable appropriate drug 
administration to TB suspects is required (26,79).  
 
2.5. Factors affecting drug resistance genotyping  
Numerous factors such as the DNA concentration, presence of PCR inhibitors, silent or excluded 
mutations and contaminants may affect the specificity and sensitivity of molecular methods; 
some of the factors are summarized in Table 2.5. Contaminants can be overcome by rigorous 
23 
 
decontamination although this may affect mycobacterial culturability, and DNA concentration 
methods have been devised but are cumbersome. Advantages of these techniques over culture 
methods include their sensitivity for detection of low level resistance and hetero-resistance 
although with a detection limit (28,83,225). The search for bactericides for sterilization of 
clinical specimens is limited as many chemicals may inhibit PCR or destroy DNA, therefore 
there is an urgent need to identify chemicals which simultaneously sterilize specimens and lyse 
mycobacterial cells but leave intact DNA for PCR. An ideal method would be one which is 1) 
rapid, 2) robust, 3) cheap, and 4) prevents amplicon contamination and 5) overcomes the factors 
listed in Table 2.5. 
 
Table 2-1 Critical concentrations for drug susceptibility testing of M. tuberculosis isolates in 
different media. 
Drug group Drug DST critical concentration (µg/ml) 
Lowenstein-Jensen Middlebrook 
7H10 
Middlebrook 
7H11 
BACTEC 
460 
MGIT 960 
Group 1 
1st line oral TB regimes 
Isoniazid * 
Rifampicin* 
Ethambutol* 
Pyrazinamide* 
0.2 
40.0 
2.0 
- 
0.2 
1.0 
5.0 
- 
0.2 
1.0 
7.5 
- 
0.1 
2.0 
2.5 
100.0 
0.1 
1.0 
5.0 
100.0 
Group 2# 
Injectable TB regimens 
Streptomycin* 
Kanamycin  
Amikacin  
Capreomycin  
4.0 
30.0 
- 
40.0 
2.0 
5.0 
- 
10.0 
2.0 
6.0 
- 
10.0 
2.0 
4.0 
1.0 
1.25 
1.0 
- 
1.0 
2.5 
Group 3 
Fluoroquinolones 
Ciprofloxacin 
Ofloxacina 
Moxifloxacinb 
2.0 
2.0 
- 
2.0 
2.0 
- 
2.0 
2.0 
- 
2.0 
2.0 
0.5 
1.0 
2.0 
0.25 
Group 4 
Oral bacteriostatic 2nd line 
TB regimens 
Ethionamide 
Prothionamide 
40.0 
40.0 
5.0 
- 
10.0 
- 
2.5 
1.25 
5.0 
2.5 
LEGEND TABLE 2.1 
The table was adapted from WHO to include only currently used drug regimens in treatment of drug resistant TB in 
developing countries. - =denotes that critical concentrations of the TB drug is not yet standardized on the specific 
media or DST system. 
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Table 2-2 Performance of phenotypic DST methods 
Phenotypic 
techniques  
Advantages Disadvantages 
TB 
drug 
Sensitivity 
range 
Specificity 
range 
References 
L
IQ
U
ID
 C
U
L
T
U
R
E
 M
E
T
H
O
D
S
 
BACTEC 460 
 Reference method for PZA 
 Low contamination rate 
 Manual, Expensive 
 High maintenance 
 Uses radioactive material which require 
special disposal systems 
 Use of glass bottles and syringe 
RIF 
INH 
 
98-100 
96-100 
 
 
 
99-100 
99-100 
 
 
 
(92,162,219) 
 
 
MGIT 
& 
BACTEC 
MGIT 960  
 Automated 
 Fluorometric 
 Rapid (8-10 days) 
 Expensive, High contamination rates 
 Highly sensitive to non-homogenous 
mycobacterial suspensions 
 
RIF 
INH 
SM 
EMB 
AMI 
CAP 
PZA 
PRO 
98-100 
100 
100 
89-100 
96-100 
92-97.4 
100 
63-75 
100 
100 
100 
95-100 
99-100 
98-100 
96.6 
98-99 
(14,92,168,190,242) 
 
BacT/Alert 3D 
system 
 Automated system 
 Colometric 
 ~15 days 
Expensive 
 
RIF 
INH 
SM 
EMB 
92-97 
96-100 
78-100 
100 
100 
95-100 
100 
98-100 
(12,29,236) 
 
MODS 
 Detects cord formation 
 Rapid (DST within 7-10 days) 
 Low cost 
 Easy to perform 
 Biosafety necessity 
 Cross contamination 
 Overestimation of growth 
 Need for high standard quality controls 
 Need for inverted microscope 
INH 
RIF 
SM 
EMB 
OFL 
93.8-100 
95-100 
51-92 
58-95 
100 
78.4-100 
82.9-100 
100 
100 
100 
 
(60,70,74,135,148,149
,165) 
 
ESP II system 
 Non-radiometric 
 Automated, Rapid, Cost 
effective 
 PZA 100 100 (110) 
Colometric methods 
MABA 
 Low cost 
 Rapid (8-14 days)  for MABA 
 Rapid (8-10 days) for TEMA 
 Rapid (7-10 days) 
 
 Read by eye/ 
 fluorometry or 
spectrophotometer 
 Multiple tests simultaneously 
 MIC determination 
Biosafety necessity (live cultures) 
 
INH 
RIF  
97-100 
93-100 
64-97 
99-100 
(32,43,175) 
 
TEMA 
 
MDR 
SM 
EMB 
94-100 
92-96 
87-94 
97-100 
93-100 
71-96 
(147) 
REMA 
MDR 
PZA 
EMB 
STR 
KAN 
ETH 
OFL 
CAP 
95-100 
100 
94 
94 
100 
100 
100 
84.2 
96-100 
98 
58 
89 
97-100 
97-100 
97-100 
97 -100 
(125,128,129,147,158,
179) 
 
S
O
L
ID
 C
U
L
T
U
R
E
 B
A
S
E
D
 M
E
T
H
O
D
S
 
TLA assay 
 Rapid 
 Inexpensive 
 Low cost 
 Less prone to contamination 
 than MODS 
One plate format 
 
MDR 
EMB 
SM 
KAN 
OFL 
100 
100 
100 
100 
100 
100 
99-100 
100 
99-100 
100 
 
(127,180,192) 
 
E-test 
 Rapid (5-10 days) 
 Simultaneous determination of 
MIC‟s 
Expensive (cost per strip and specialized 
incubator CO2) 
MDR 
SM 
99-100 
84-100 
100 
100 
(3,64,162) 
 
NRA 
 Rapid (7-14 days) 
 Nitrate reductase negative 
 M. tuberculosis is rare (<1) 
Most RGM and M. kansasii can reduce nitrate 
to nitrite 
INH 
RIF 
SM 
EMB 
PZA 
95-100 
96-100 
64-100 
93-100 
94 
87-100 
93-100 
66-100 
84-98 
98 
(1,13,31,115,142,143,
146,147,155,195,202, 
213,230) 
 
Mycobacteriophage based assay 
Luciferase 
reporter system 
 Rapid (~3 days) 
 Simple 
 More sensitive than BACTEC 
460 
 
 Only infection of live bacilli 
 (treatment monitoring) 
 Biosafety necessity 
 Only live bacilli infected 
 Non-specificity 
 High contamination rates High rates of 
non-interpretable results 
RIF 
INH 
SM 
EMB 
100 
79-100 
79-100 
33-94 
89.2-100 
96-98 
69-93 
95-100 
(17,67,78,219) 
 
FastPlaque 
assay 
INH 
RIF  
SM 
98-100 
94-100 
94 -96 
93-100 
95-100 
100 
(8,56,66,134,185,219) 
RGM=Rapid growing mycobacteria 
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Table 2-3 Gene(s) associated with drug resistance in M. tuberculosis 
 
TB drug 
Gene(s) Prominent mutations References 
Isoniazid katG 
inhA 
oxyR, ahpC, furA, ndh 
katG-315 
-C15T, -24, -16, -8, -17 
 
(103,112,172) 
Rifampicin rpoB rpoB-516, -526, -531, -533 (134,172,215) 
Pyrazinamide (pH 5.5) pncA, IS6110 insertion  (22,121,193) 
Ethambutol embCAB embB-306 (93,172) 
Streptomycin rpsL 
rrs 
gidB 
 (134,163,172) 
Amikacin/kanamycin rrs rrs1400 (5,106,216) 
Capreomycin tlyA  (131,132,210) 
Ofloxacin 
Ciprofloxacin 
gyrA 
gyrB, inhA, ethA, ethR, alr 
inhA21, 94, 44 
gyrA90, 91, 94 
(52,72,73) 
Ethionamide Eta/ethA  (19,113,151,178) 
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Table 2-4 Molecular assays with their respective overall accuracies for detection of drug 
resistance   
Genotypic assays 
TAT* 
(hours) 
TB drug 
resistance 
Sensitivity 
range 
Specificity 
range 
References 
 
RT-PCR 
 
~3hrs 
INH, 
RIF 
OFX 
83-98% 
89-100% 
96% 
100% 
99-100% 
100% 
 
(105,181,232,232) 
 
Cepheid GeneXpert 
System 
~2 hrs RIF 97-100% 99-100% (26,79) 
MLPA assay ~2 hrs 
RIF 
INH 
EMB 
70-85% 
65-80% 
45-65% 
100% (21)  
MTBDR assay ~2 hrs 
INH 
RIF 
71-100% 
96-99 
100 
97.8-98 
 
(31,40,82,123), 
MTBDRplus assay ~2 hrs 
RIF 
INH 
95 -100% 
82-95.3% 
98-100% 
99-100% 
 
(18,82,86,118,159) 
MTBDRsl ~2 hrs 
EMB 
CAP 
KAN 
AMI 
FLQ 
57-64.2% 
80-100% 
77-100% 
83-100% 
75-90.2% 
92-100% 
98-100% 
100% 
100% 
96-100% 
 
(28,83,104) 
Inno LiPA Rif.TB ~2 hrs RIF 87-98.6% 87-100% 
 
(91,162,194,203) 
*TAT refers to turn around time to obtain results when performing the assays on decontaminated specimens or crude 
cultures.  
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Table 2-5 Factors that negatively impact on drug resistance detection by molecular techniques 
Amplification/detection inhibitors References 
Hetero-resistance subpopulations (28,79,133,180,225) 
Mixed mycobacterial species (44,49,51) 
Type, length and position of probes (117,184,245) 
Difficulty to design probes for certain regions, Instability of probes due to 
repeated thawing 
High thermal duplex stability of mycobacterial genome due to high GC 
content 
(96,109,223) 
 
Unknown/novel mutations, Unknown /Excluded genes, Silent mutations (4,28,35,97,120) 
Mutation prevalence in different geographic regions (160) 
Loss of DNA integrity following multiple decontamination steps 
 
(25,58,100,208,234) 
PCR inhibitors 
Amount of mycobacterial cells in clinical specimens 
DNA concentration and extraction 
Amplicon contamination 
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CHAPTER 3 
3. Materials and methods 
 
Approval for sputum specimen collection and use of clinical mycobacterial isolates as well as 
ethics clearance was obtained from the Stellenbosch Human Research Committee.  
 
3.1. Experimental approach: Project 1- Sputum processing 
3.1.1. Aim 
To develop a methodology which will ensure preservation of DNA extracted from sputum for 
downstream application such as PCR without compromising the ability of the non-viable 
mycobacterium to stain with the Ziehl-Neelsen or Auramine-O stain. A sputum processing 
methodology which yields sterile sediments of M. tuberculosis is devised. The experimental 
approach for the bactericide protocol is outlined in figure 3.1.   
 
3.1.2. Bactericide selection 
Four bactericides were selected based on published literature on their bactericidal nature and 
activity, low or lack of toxicity or irritation on contact with skin (Table 3.1).  
 
Table 3-1 Selected bactericides 
Bactericide Active moiety Concentration References 
Sodium Hypochlorite 
(NaOCL) 
Hypochlorous acid 
(HOCL) 
(2% v/v), (5% v/v) and (10% v/v) 
[final concentration]  
(1% v/v), (2.5% v/v) and (5% v/v) 
(1,8) 
Incidinplus Glucoprotamin (10% v/v) [final concentration] (5% v/v) (28,32) 
Ultraseptin®aktiv Peracitic acid (C2H4O3) (4% w/v) [final concentration] (2% v/v) (25) 
Ortho-phthalaldehyde (OPA) OPA (1%w/v) [final concentration] (0.5% v/v) (6,24,26) 
Ethanol 
C2H5OH 
C2H5OH [concentration](70% v/v)  (22,33) 
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3.1.3. Bactericides and BCG Pasteur cells 
3.1.3.1. Bactericidal treatment 
Prior to determination of bactericidal efficiency on sputa, the bactericides listed in Table 3.1 with 
the exception of OPA were tested on BCG Pasteur cells to determine the concentration and time 
duration which would result in effective mycobacterial killing. Bactericidal concentrations and 
time durations previously reported in the literature for the specified bactericide were investigated 
(1,6,8,24,25,28). Experimentation with the live BCG Pasteur cell cultures was done inside a 
Biohazard Class II fume hood. BCG Pasteur cells were inoculated on 7H9 liquid medium 
(Becton Dickinson, Sparks, MD, USA) supplemented with 0.2 % (v/v) glycerol, 0.1 % Tween-80 
and 10% ADC) and incubated at 37°C to mid-log phase (optical density of 0.7-0.8) at a 
wavelength of 600nm. Culture aliquots (500µl) were made and treated with equal volumes of the 
respective bactericides at the suggested concentrations (Table 3.1) at different time durations (1, 
5, 10, 15, 20, 30 minutes). A positive (no bactericide treatment) and a negative (no BCG Pasteur 
cells) control were also included. The specimens were then centrifuged for 15 minutes at 3000 
rpm at 4°C. The supernatant was discarded and the pellet was resuspended in 1.5ml of BACTEC 
MGIT 960 medium and mixed gently by vortexing for 15-60s.  
 
3.1.3.2. Killing efficacy after treatment  
The resuspended pellets (100µl) was inoculated in 7H10 Middlebrook agar medium. Growth was 
assessed every 2-3 days for 25 days. Only the bactericide(s) which inhibited growth of the BCG 
cells at time durations no longer than 30 minutes were further investigated. Aliquots (50µl) of 
the pellet supernatants were made and subjected to PCR amplification of the rpoB, katG, and the 
RV2629 gene (19,21,30,31) (Table 3.2). A 695-bp fragment of the Rv2629 gene was amplified 
with the set of primers provided in table 1.3. The PCR reaction was performed under the 
following temperature profile: 15 min denaturation at 95° C followed by 40 amplification cycles 
(each cycle: 94°C for 1 min, 62°C for 1 min, 1 min extension at 72°C) and an elongation step of 
10 min at 72°C. The PCR protocol for amplification of the katG (419-bp) and rpoB (437-bp) 
gene was done as follows; 15 min denaturation at 95°-8 C followed by 40 amplification cycles 
(each cycle: 94-8°C for 1 min, 62-8°C for 1 min, 1 min extension at 72-°8C) and an elongation 
step of 10 min at 72-°8C. The PCR products were then electrophoresized on 1.5% agarose gel. 
Ten microlitres of the same supernatants was used for smear microscopy. Bactericides with 
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bactericidal concentrations which allowed PCR amplification and did not influence stainability 
of mycobacteria after treatments were then investigated on M. tuberculosis (R439) and sputum 
specimens containing M. tuberculosis.  
 
3.1.4. Bactericide(s) and M. tuberculosis strains (R439) 
3.1.4.1. Bactericidal treatment  
Culture aliquots (500µl) of R439 grown in 7H9 liquid medium (Becton Dickinson, Sparks, MD, 
USA) supplemented with 0.2 % (v/v) glycerol, 0.1 % Tween-80 and 10% ADC) and incubated at 
37°C to mid-log phase (optical density of 0.7-0.8) were made. The aliquots were treated with the 
candidate bactericides at concentrations and time durations which met the required criteria in 
BCG Pasteur cells. A positive (no bactericide treatment) and a negative (no R439 cells) control 
were also included. The specimens were then centrifuged for 15 minutes at 3000 rpm at 4°C. The 
supernatant was discarded and the pellet was resuspended in 2.5 ml of ddH2O and mixed gently 
by vortexing for 15-30s.  
 
3.1.4.2. Killing efficacy after treatment 
To determine the bactericidal efficacy or post treatment viability, the treated, positive and 
negative controls were cultured in various media. A volume of 100 µl of the pellet suspension 
was plated in (i) Middlebrook 7H10 agar, and a volume of 500µl was inoculated in each of the 
following media (ii) Middlebrook 7H9 (Becton Dickinson, Sparks, MD, USA) supplemented 
with 0.2 % (v/v) glycerol, 0.1 % Tween-80 and 10% ADC) (iii) BACTEC MGIT 960 vials 
supplemented with PANTA (BD Diagnostics Systems, Sparks, MD, USA) and incubated at 
37°C. Growth was assessed for the different media in the following manner: 7H10 agar plates 
were examined for growth every 5-7 days for 25 days. Absorbance readings for the 7H9 cultures 
were measured every 7 days for 28 days. The BACTEC MGIT 960 vials were inoculated up to 
42 days.  
 
3.1.5. Bactericide(s) and sputum specimens  
3.1.5.1. Sputum collection 
Sputum specimens (n=300) were collected from June 2009 until June 2010 from TB suspects at 
the Tygerberg hospital, Western Cape, South Africa. Smear microscopy identified 216 acid fast 
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bacilli (AFB) negative and 84 AFB positive specimens. The sputum specimens were graded 
based on the AFB count system of the International Union against Tuberculosis and Lung 
Disease (5). The eighty four (n=84) AFB positive and 8 AFB negative sputa were tested (Table 
4.2). Sixty five of  these (65/84) AFB positive specimens with volumes ≥20 ml were split into 
two equal portions and liquefied and homogenized with an equal volume of Sputagest activial 
(4% v/v) (n= 45) or reconstituted NALC-NaOH (4%) (n=20) (figure 4.1). Twenty five of the 
forty five (25/45) sputum specimens liquefied with sputagest activial were exposed to 
ultraseptin®aktiv for 15, 20, and 30 minutes respectively (figure 4.1). Twenty of the forty five 
(20/45) sputum specimens liquefied with sputagest activial and exposed to OPA (figure 4.1). 
Equal proportions (10) of the 20 specimens liquefied with NALC-NaOH were exposed to 
ultraseptin®aktiv and OPA for 15, 20 and 30 minutes respectively (figure 4.1). The remaining 
nineteen specimens from the eighty four (19/84) with volumes <20 ml and bacterial loads 
varying between 3+ to scanty were not split but only liquefied with sputagest activial (2% v/v) 
and exposed to ultraseptin®aktiv (n=9) and OPA (n=10) for 30 minutes respectively (figure 4.1). 
The 8 AFB negative sputa were also split into 3 portions and exposed to the OPA or 
ultraseptin®aktiv for 15, 20 and 30 minutes respectively and inoculated on BACTEC MGIT 960 
along with the above sputum specimens (figure 4.1). 
 
Table 3-2 Bacterial load and quality of sputum specimens. 
Sputum type Bacterial load Number of  sputum specimens 
Blood stained - 
Scanty 
+ 
++ 
+++ 
4 
3 
3 
3 
12 
Mucoid - 
Scanty 
+ 
++ 
+++ 
2 
4 
8 
8 
23 
Watery (saliva) - 
Scanty 
+ 
++ 
+++ 
2 
3 
2 
6 
9 
TOTAL 92 
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3.1.5.2. Bactericidal treatment  
Smear positive sputum specimens were liquefied with an equal volume of Sputagest Activial or 
NALC-NaOH and vortexed for 30 to 60s and placed in an orbital shaker (330rpm at 37°C) for 15 
minutes according to manufacturer‟s instructions (Mast Diagnostics, Merseyside, UK). An equal 
volume of bactericides which met the required conditions in R439 isolates were added, vortexed 
for 30s and allowed to stand at room temperature. The specimens were then centrifuged for 15 
minutes at 3000 rpm at 4°C after which the supernatant was discarded into a container with a 
phenol based disinfectant (incidinplus). The pellet was then resuspended in 1.5 ml of BACTEC 
MGIT 960 medium and mixed gently by vortexing for 15-30s.  
 
3.1.5.3. Killing efficacy after treatment of sputum specimens 
The bactericidal efficacy or post treatment viability of M. tuberculosis in sputum specimens was 
deduced as described on R439 cells. Absorbance readings on sputum specimens treated with 
OPA were read at 740nm (24).   
 
3.1.5.4. Verification of positive cultures 
If growth on the cultures was observed after bactericide treatment, the following was done to rule 
out contamination; (i) Ziehl-Neelsen (ZN) staining and (ii) Blood agar plating.  
 
ZN staining and blood agar 
For ZN staining, 10µl of culture was smeared and heat fixed (heated for 2 hours at 100 °C), 
stained with carbol-fuchsin (Becton, Dickinson and Company, Maryland, USA), and 
decolourized with 5% acid alcohol. The smear was then counterstained with methylene blue 
(Becton, Dickson and Company, Maryland, USA) and read under the microscope for AFB. M. 
tuberculosis is an AFB which retains the carbol-fuchsin dye when heated and treated with 
acidified organic compounds and it will appear pink in a contrasting background when the ZN 
test is done. Mycobacterial growth is indicated by formation of mycobacterial strings and 
tangles. On blood agar, 100µl of the culture was plated and incubated for two days (M. 
tuberculosis does not grow on blood agar within 2 days). 
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3.1.5.5. Negative cultures after bactericide treatment 
After AFB positive specimens flag off as negative on the MGIT 960 (42 days) and no growth is 
observed on either 7H9 or 7H10 media, the bactericide was considered to be an effective reagent 
for killing M. tuberculosis. Aliquots of 10µl and 50µl of the sediments with negative cultures 
were further evaluated for mycobacterial DNA integrity by PCR and stainability by ZN and 
auramine-O staining respectively. 
 
3.1.5.6. Detection of M. tuberculosis by microscopy 
ZN and Auramine-O stained slides were prepared from the sputum sterilized sediments to check 
for the stainability of the mycobacteria following treatment with the respective bactericide. 
 
Auramine-O staining 
Ten microlitres of culture was smeared onto slides and heat fixed (heated for 2 hours at 100 °C), 
then stained with auramine-O and decolourized with 5% acid alcohol. The smear was then 
counterstained with 0.05% potassium permanganate (Becton, Dickson and Company, Maryland, 
USA) and read under fluorescence microscope. The auramine-O stain contains fluorochromes 
which have an affinity for the mycolic acid in the cell walls for mycobacteria. Potassium 
permanganate helps prevent non-specific fluorescence. Under fluorescence microscope, 
mycobacteria as a result of bound fluorochromes appear as bright yellow, luminous rods against 
a dark background. Mycobacterial growth is indicated by formation of mycobacterial strings and 
tangles. 
 
3.1.5.7. Determination of the DNA integrity by PCR 
Random genes in the M. tuberculosis genome were amplified to confirm that the DNA integrity 
is not compromised and the bactericide does not influence the PCR reaction. The rpoB, katG, 
and RV2629 genes were amplified with the previously described primer sets  (Table 3.2) (14,21). 
The PCR based MTBDRplus assay was also verified on the same set of supernatants and was 
done according to the manufacturer‟s instructions (Hain Lifescience, Nehren, Germany).  
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Table 3-3 Primer sets for gene amplification 
Primer Sequence Tm 
Fragment 
length 
 
References 
rpoB gene 
rpoB Forward 
rpoB Reverse 
 
TGGTCCGCTTGCACGAGGGTCAGA 
CTCAGGGGTTTCGATCGGGCACAT 
 
72oC 
 
 
437bp 
(21) 
katG gene  
RTB 59 Forward 
RTB 38 Reverse 
 
TGGCCGCGGCGGTCGACATT 
GGTCAGTGGCCAGCATCGTC 
 
62°C 
 
419bp 
 
(21) 
RV2629 gene 
RV2629 Forward 
RV2629 Reverse 
 
ATGGGCAACAGTGGGTTTG 
AGTTCATTCGGATGGCTTCTT 
 
62°C 
 
695bp 
 
(14) 
  
56 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Microscopy PCR amplification 
rpoB, katG and  
RV2629 gene 
MTBDRplus assay 
Mycobacterial culture  
Middlebrook 7H9 
medium  
Middlebrook 
7H10 agar 
BACTEC MGIT 
 960 system 
Sputum (≥20 ml) Sputum (<20 ml) / Scanty  1+ 
Bactericide (A) 
(15, 20 and 30 minutes) 
 
Bactericide (B) 
(15, 20 and 30 minutes 
Bactericide (A) or (B)  
(30 minutes) 
Sputum splitting (= portions) 
Suspension of pellet (1.5ml Middlebrook  MGIT 960 medium) 
Centrifugation (3000 rpm @4°C, 15 min)  
BCG Pasteur cell culture (500µl) 
Bactericide (A) or (B) or (C) 
(1, 5, 10, 15, 20 and 30 minute(s) 
 
Liquification (Sputagest 
activial) 
 
Liquification (NALC-NaOH) Liquification (Sputagest activial) 
Figure 3-1 Schematic representation of the bactericide protocol. 
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3.2. Experimental approach: Project 2- Influence of NTM’s on drug resistance testing 
3.2.1. Aim  
To determine the influence of the presence of non tuberculous mycobacterium (NTM‟s) on the 
detection of drug resistant TB by the PCR based MTBDRplus assay.  
 
3.2.2. Selection of mycobacterial isolates 
Ten most prevalent clinically relevant NTM‟s associated with disease resembling TB 
(2,3,16,27), isolated from M. tuberculosis infected and/or in immunocompromised (HIV/AIDS) 
patients were selected (Table 3.4). ATTC cultures, clinical isolates and other isolates from the 
Centre of Disease Control and Prevention (CDC) of the different NTM‟s were obtained from an 
existing local sample bank maintained at the Stellenbosch University, Western Cape, South 
Africa. 
 
Table 3-4 Selected non-tuberculous mycobacterial species and drug resistant isolates. 
Mycobacterial species Isolates origin References  
M. avium TMC724 (13,18)  
M. terrae 2209 Ravensmead/Uitsig a, SA (7,23) 
M. intracellulare ATCC 15985 (9) 
M. kansasii CDC Jun 2005 (2,4,15) 
M. fortuitum ATCC 6841 (10) 
M. bovis ATCC 19210 (17) 
M. xenopi CDC 2004 (7) 
M. chelonae CDC  Jan 2008 (7) 
M. peregrinum 2708/2111 Ravensmead/Uitsig a, SA (7) 
M. abscessus CDC Jan 2007 (29) 
Beijing R439  George a, SA (20) 
LEGEND TO TABLE 3.4 
CDC= Centre for Disease Control and Prevention, TMC724 =Trudeau Mycobacterial Culture Collection,  
a = Clinical strains, SA= South Africa 
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The NTM‟s were confirmed by 16SrRNA, gyrB sequencing as well as with a speciation assay 
(Genotype Mycobacterium CM) (Hain Lifescience, Nehren, Germany) (11,12). Segments of the 
16SrRNA and gyrB gene were amplified using primer sets provided in Table 3.4. The 
amplification reaction was subjected to 35 cycles with a denaturation step at 95°C for 1 min, an 
annealing step at 63°C for 1 min, and an extension step at 72°C for 2 min. PCR amplification of 
a region (approximately 577 bp) of the 16SrRNA gene was performed. 5 ml of extracted DNA 
was added to 45 ml of the PCR amplification mixture, with the final 50-ml volume containing 
1.25 U of Taq DNA polymerase (Promega Corporation,Madison, Wis.), 50 mM KCl, 10 mM 
Tris-HCl (pH 9.0), 1.5 mM MgCl2, 0.1%Triton X-100, deoxyribonucleotides, each at a 
concentration of 150 mM (Pharmacia,San Francisco, Calif.), 30 pmol of each of the two primers, 
and 50 mg of 8-methoxypsoralen (Sigma Chemical Company Ltd., Dorset, United Kingdom) per 
ml, and the mixture was overlaid with light mineral oil (Sigma Chemical Company Ltd.). The 
PCR amplifications were performed in a thermocycler (Perkin-Elmer Corporation, Norwalk, 
Conn.), and the amplification mixtures were subjected to 4 min of denaturation at 94°C and 40 
cycles of 94°C for 1 min, 60°C for 2 min, and 72°C for 2 min, followed by a final extension 
period of 72°C for 7 min and refrigeration. The PCR products were then sent for sequencind at 
the Central Analytic Facility at Stellenbosch University, Cape Town, South Africa.  
 
Table 3-5 Primer sets for gene amplification 
Primer Sequence Tm 
Fragment 
length 
References 
16SrRNA gene 
16SrRNA Forward 
16SrRNA Reverse 
 
AGA GTT TGA TCC TGG CTC AG 
GCG ACA AAC CAC CTA CGA G 
 
60 oC 
 
577bp 
 
(12) 
gyrB gene 
gyrBspec-Forward 
gyrBspec-Reverse 
 
TCG GAC GCG TAT GCG ATA TC 
ACA TAC AGT TCG GAC TTG CG 
 
60 oC 
 
1020bp 
 
(12) 
 
Pure and crude DNA from a well characterized clinical isolate (R439) of M. tuberculosis was 
selected from the same sample bank (Table 3.4). The clinical isolate was selected based on its 
possession of mutations in the katG 315 ACA (INH resistance) and rpoB 531 TTG (RIF 
resistance) gene. Only mycobacterial DNA without any background of other mycobacterial 
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species based on genotypic pattern on the Genotype Mycobacterium CM was used.  
 
The DNA concentration of the respective NTM‟s and M. tuberculosis isolates was determined by 
spectrometry. The DNA concentration necessary was determined as the minimum amount of 
DNA required for standard PCR. Dilution of drug resistant M. tuberculosis clinical isolate with 
increasing concentrations of NTM was made. The ratios ranged from 1:1 to 1:200 with 
increasing NTM DNA and the M. tuberculosis DNA kept constant.  
 
3.2.3. Known mixed NTM and M. tuberculosis in clinical isolates  
Results from a study conducted in our laboratory identified 4 clinical isolates with mixed NTM 
and M. tuberculosis by analyzing their 16SrRNA and GyrB gene sequences (Table 3.5). The 
clinical isolates (6865, 7426, 7690, and 7618) were LJ cultures from sputum samples obtained 
from TB suspects at Ravensmead /Uitsig residents near Tygerberg hospital (Table 3.6).  
  
60 
 
Table 3-6 Mixed NTM and M. tuberculosis clinical isolates 
Clinical isolate 
reference nr 
16S rRNA sequencing GyrB sequencing 
6865 M. kumamotonense M. tuberculosis 
7426 M. triviale M. tuberculosis 
7618 M. terrae M. tuberculosis 
7690 M. acapulcensis M. tuberculosis 
 
To determine whether the PCR-based assays (MTBDRplus) will be able to detect the M. 
tuberculosis in the NTM/TB mixed isolates. The Genotype Mycobacterium CM and 
MTBDRplus assay were performed on the four clinical isolates (Table 3.6). The results were 
then compared with those obtained from 16S rRNA and GyrB sequencing (Table 3.5). 
 
3.2.3.1. MTBDRplus assay on sputum specimens 
Randomly selected sputum specimen sediments from Project 1 were subjected to the 
MTBDRplus assay. The sputum specimens were speciated by 16SrRNA, gryB sequencing and 
with the Mycobacterium Genotype CM. These results were then compared to those of the 
MTBDRplus assay.  
 
3.3. Experimental approach: Project 3- Hetero-resistance detection with the MTBDRplus 
assay 
3.3.1. Aim 
To determine the detection limit of the MTBDRplus assay for identifying drug resistance in 
hetero-resistant isolates. Hetero-resistance is defined by presence of wild type and drug resistant 
isolates in the same sample.  
 
Pure DNA of MDR (R2126) and a drug susceptible (212) TB isolates was obtained from the 
South African Western Cape (SAWC) study. The MDR-TB isolate has known katG 315 ACA 
(INH resistance) and rpoB gene 531 TTG mutations (RIF resistance) whereas the susceptible 
isolate has wild type sequences for both RIF and INH sequences. Their DNA concentration was 
determined and the mixed MDR and drug susceptible ratio‟s was made as described previously 
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in the study for NTM‟s. The ratios ranged from 1:1 to 1:200 with the MDR-TB isolate ratio kept 
constant. The MTBDRplus assay was then done on the specimens with the respective ratios 
according to the manufacturer‟s instructions. 
 
3.4. Experimental Approach: Project 4- Development of a closed line probe assay system 
3.4.1. Aim 
To develop a single tube closed line probe device for the MTBDRplus assay which will prevent 
contamination 
 
3.4.2. Development of a device which will prevent contamination during the MTBDRplus 
assay  
A challenge with the 12-blot line-probe based MTBDRplus assay is to prevent cross 
contamination which may occur during the multiple manual steps done before obtaining results. 
An automated 48-blot system which allows 48 samples or less to be genotyped simultaneously is 
less prone to cross contamination than the manual system. However, for implementation at 
health care clinics where less than 20 TB suspects a day may present at the clinic, the 48 blot 
system is less advantageous. To overcome the challenges with PCR amplicon contamination, a 
single tube closed line probe system would be an advanced step forward.  
 
The device that was developed consists of wire clumps, rubber tubes, plastic reservoir, plastic 4-
way connector and modified 7ml plastic tubes (figure 3.2). The rubber tubes are divided into 7 
compartments by wire clumps. Each compartment contains the reagents used in the different 
steps followed during the MTBDRplus assay (figure 3.3). These compartments will respectively 
contain the hybridization buffer, stringent wash solution, conjugant, 2 sections for the rinse 
solution, ddH2O and finally the substrate. A single strip of the MTBDRplus membrane is 
inserted inside the device and closed by the wire clumps. The denaturing reagent (20µl) is first 
mixed with the PCR amplicons (20µl) into a 1ml tube before introduction of the two into the 1st 
chamber. After the hybridization buffer is allowed to mix with the membrane, the denatured 
amplicons (40µl) are injected with a 1ml syringe into the rubber tube on the compartment with 
the membrane. The different reagents are pushed through the wire clumps to the compartment 
containing the membrane. The single tube device is placed onto a shaking oven at 45ºC during 
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the hybridization and stringent wash step; the rest of the assay is performed in a biosafety level II 
cabinet at room temperature. This is a completely sealed device and no amplicons will leak out 
of the system. This system is only a prototype for proof of concept and in the long run, it may 
offer prospects for automation for patenting.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
All the materials were bought from local suppliers. The following samples (blank, MDR-TB and 
susceptible clinical isolates) were tested on the single tube enclosed method. 
  
 
 
Figure 3-2 Single tube line probe assay prototype 
 
7ml plastic tube 
2ml rubber tube 
4 way connector 
Wire clamp 
Modified tubes 
2ml rubber tube 
4 way connector 
Wire clamp 
Rinse 
solution 
Rinse solution 
Stringent buffer/ 
reservoir 
Hybridization buffer/ 
reservoir Strip membrane 
Rinse 
solution  
Conjugation buffer 
Substrate 
buffer 
Figure 3-3 Material used to construct 
the single tube line probe prototype 
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MATERIALS 
 
Acid alcohol (5%)    Hydrochloric acid (5ml) 
Ethanol (100ml) 
Carbol-fuchsin ZN stain 
Methylene blue 
Potassium permanganate (0.05%) 
 
Sputagest Activial    Dithiothreitol (DTT) (0.1g) 
Sodium chloride (0.78g) 
Potassium chloride (0.02g) 
Disodium hydrogen phosphate (0.112g) 
Potassium dihydrogen phosphate (0.02g) 
dH2O to make up 100ml of sputum digestant 
(pH of 7.4 ± 0.2) 
 
Sodium hypochlorite working stock Commercial Sodium Hypochlorite solution (10%) 
      dH2O (90%) 
 
Ortho-pthalaldehyde (1% w/v)  Ortho-pthalaldehyde (1g) 
      dH2O (100 ml)  
 
Ultraseptin®Aktiv (4%)   Ultraseptin®Aktiv (20g) 
      dH2O (500 ml) 
 
Incidinplus (10%)    Concentrated Incidinplus (10%) 
      dH2O (90%) 
 
Ethanol (70%)     Absolute Ethanol (70%) 
      dH2O (30%) 
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Sodium bisulphite (1% w/v)   Sodium bisulphite (1g) 
      dH2O (100ml) 
    
     
Middlebrook 7H9 medium:    7H9 medium (4.7g) 
      dH2O (900ml) 
      Glycerol (2ml) 
      Polysorbate (Tween-80) (0.5ml) 
 
ADC:      BSA (25g) 
      Glucose (10g) 
      Catalase (0.75ml) 
      dH2O to make up 500ml 
 
Middlebrook 7H10 medium:   7H10 medium (19g) 
      dH2O (900ml) 
      Glycerol (5ml) 
 
OADC:     Bovine Albumin (Fraction V) (50.0g) 
      Dextrose (20.0g) 
Catalase (0.03g) 
      Oleic acid (0.6 ml) 
      Sodium Chloride (8.5g) 
      dH2O to make up 1L 
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CHAPTER 4 
4. Results 
 
This chapter will be divided into the following sections: (i) identification of an efficient 
bactericide agent against M. tuberculosis which does not compromise the mycobacterial cell wall 
for staining and DNA integrity for PCR amplification (project 1 in Materials and Methods), (ii) 
identification of factors which may influence the reliability of the MTBDRplus assay (project 2-
4 in Materials and Methods).  
 
4.1. Bactericidal efficacy  
4.1.1. Bactericidal efficacy on BCG Pasteur cells  
In an attempt to identify an efficient bactericide against M. tuberculosis, BCG Pasteur cells were 
exposed to candidate bactericides (sodium hypochlorite (NaOCl), 70% ethanol (EtOH), 
incidinplus and ultraseptin®aktiv) at different concentrations and time durations followed by 
culture and PCR amplification. 
 
Figure 4.1 shows Middlebrook 7H10 agar plates of BCG Pasteur cells exposed to 2% w/v of 
ultraseptin®aktiv (A), 5% v/v of incidinplus (B) and 1% v/v, 2.5% v/v and 5% v/v  of  NaOCl 
(C) [final concentrations] for different time durations (30, 20, 15, 10, 5, 1 minute(s) respectively. 
Complete growth inhibition was observed on cells exposed to either ultraseptin®aktiv (2%) (A), 
incidinplus (5%) (B) and NaOCl (5%) (C) within 1 minute of contact up to 30 minutes. NaOCl at 
a concentration of 1% v/v did not inhibit growth of the cells exposed for 1 minute to 30 minutes. 
Partial growth inhibition was observed following 2.5% NaOCl exposure for 15 minutes and after 
30 minutes complete growth inhibition occurred [data not shown]. Also included in figure 4.1A 
is an agar plate of BCG Pasteur cells which grew even after exposure to 70% EtOH (ii) for 30 
minutes. With each bactericide tested, positive and negative controls were also included. The 
positive and negative controls were untreated BCG Pasteur cells and media inoculated without 
BCG Pasteur cells respectively. As expected, growth was observed on the positive controls and 
not on the negative controls.  
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(A) Ultraseptin®aktiv (2%) 
(i) (ii) 
(iv) (v) (iii) 
(vii) (ix) (viii) (vi) 
 
(B) Incidinplus (5%) 
(i) (ii) 
(iii) (iv) (v) 
(vi) (vii) (viii) 
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Figure 4-1 BCG Pasteur cells exposed to bactericides. 
 
LEGEND TO FIGURE 4.1 
Figure 4.1A. Agar plates with (i) untreated BCG cells (positive control), (ii) BCG cells exposed to 70% EtOH for 
30 minutes, BCG cells treated with ultraseptin®aktiv for (iii) 30, (iv) 20, (v) 15, (vi) 10, (vii) 5 and (viii) 1 minute(s) 
and an agar plate with (ix) no BCG cells inoculated. Figure 4.1B. agar plate with (i) untreated BCG cells, (ii) BCG 
cells exposed to incidinplus for (iii) 30, (iv) 20, (v) 15, (vi) 10, (vii) 5 and (viii) 1 minute(s) and an agar plate with 
(ix) no BCG cells inoculated. Figure 4.1C. Agar plates with (i) untreated BCG cells, (ii) BCG cells exposed to 
NaOCl for (iii) 30, (iv) 20, (v) 15, (vi) 10, (vii) 5 and (viii) 1 minute(s) and an agar plate with (ix) no BCG cells 
inoculated. 
 
 
 
 
 
 
(C) NaOCl (5%) 
(i) 
(ii) 
(iii) (iv) (v) 
(vi) (vii) (viii) 
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4.1.2. DNA integrity 
To investigate whether the integrity of mycobacterial DNA was retained in BCG Pasteur cells 
following inhibition of growth due to exposure to various bactericides, (Ultraseptin®aktiv (2% 
w/v), NaOCl (5% v/v) and Incidinplus (5% v/v) [final concentrations]) for 1,5 ,10, 15, and 30 
minute(s), three genes (rpoB, katG and RV2629) were amplified. 
 
Figure 4.2 shows representative agarose gel pictures of PCR products of the rpoB gene after 
exposure to ultraseptin®aktiv, incidinplus and NaOCl. Both NaOCl (figure 4.2A) and incidinplus 
(figure 4.2B) completely damages the DNA even after 1 minute exposure.  From figure 4.2C, it 
is evident that ultraseptin®aktiv does not damage the DNA integrity even after 30 minutes of 
treatment. 
 
Of the three candidate bactericides evaluated ultraseptin®aktiv was the most promising as it 
enabled sterilization of BCG Pasteur cells and amplification of the candidate genes [only rpoB 
gene results shown].  
 
 
 
 
 
 
Figure 4-2 PCR amplified products of the rpoB gene on agarose gel after bactericide treatment 
  
LEGEND TO FIGURE 4.2 
Agarose gel of the rpoB gene PCR amplicons from BCG Pasteur cells exposed to (A) NaOCl for 30, 20, 15, 10, 5 
and 1 minute(s) (B) incidinplus and (C) Ultraseptin®aktiv for the same time durations. 
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During the course of this study, an additional bactericide, ortho-phthalaldehyde (OPA) was 
identified in the literature as an efficient bactericide against mycobacteria. OPA was therefore 
also tested along with ultraseptin®aktiv against mycobacteria (1). 
 
Both ultraseptin®aktiv (2%) and OPA (0.5%) were also bactericidal against a clinical isolate of 
M. tuberculosis which was inoculated to mid-log phase (optic density of 0.8) after 30 minutes 
exposure and did not induce DNA damage [data not shown].  
 
4.1.3. Bactericidal efficacy on M. tuberculosis and on sputum specimens 
To investigate whether ultraseptin®aktiv (2%) [final concentration] and OPA (0.5%) [final 
concentration] displayed bactericide activity against raw sputum specimens of different quality 
(bloody, mucoid or watery) and varying bacterial loads (scanty to 3+) were exposed for 15, 20 
and 30 minutes. AFB negative sputa were included in the experiments as negative controls.  
 
Mycobacterial growth was observed after 3 to 14 days on BACTEC MGIT 960 system in 19/34 
and 15/34 liquified with NALC-NaOH or sputagest activial followed by exposure for 15 and 20 
minutes to ultraseptin®aktiv respectively. Growth was also observed after 6 to 15 days on 
BACTEC MGIT 960 system in 12/30 specimens and 7/30 exposed for 15 minutes and 20 
minutes respectively to OPA regardless of the liquification method (NALC-NaOH or sputagest 
activial). No growth was observed on either Middlebrook 7H9 liquid (inoculated for 25 days), 
Middlebrook 7H10 agar (inoculated for 28 days) or on BACTEC MGIT 960 system (inoculated 
for 42 days) after 30 minutes exposure to either sputagest activial or NALC-NaOH liquefied 
OPA (n= 44) or ultraseptin®aktiv (n=40) sterilized specimens.  
 
Of the sputum specimens liquefied with NALC-NaOH and exposed to either OPA (n= 44) or 
ultraseptin®aktiv (n= 40) for 30 minutes, PCR amplification was inhibited in 33/40 specimens. 
Figure 4.3 shows representative microscopic results after auramine-O and ZN staining of AFB 
positive sputum specimens unexposed as well as exposed to OPA and ultraseptin®aktiv for 30 
minutes respectively. These results show that ZN and auramine-O staining can be obtained after 
exposure to both ultraseptin®aktiv and OPA. However, background fluorescence was observed 
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on sputum specimens stained by auramine-O after OPA exposure indicating that OPA may not 
be an appropriate candidate for microscopic identification of AFB.  
 
Figure 4.4A and 4.4B shows representative agarose gel electrophoresized products and 
MTBDRplus assay results after sputum specimen graded as (3+ to scanty) were liquefied with 
sputagest activial and exposed to OPA or ultraseptin®aktiv for 30 minutes. Both bactericides did 
not hinder PCR amplification (figure 4.4A) of M. tuberculosis DNA or the MTBDRplus assay on 
specimens liquefied with sputagest activial (figure 4.4B). 
 
Mycobacterial DNA could still be amplified from specimens with very low bacterial load (scanty 
up to 3+) (figure 4.4A). From figure 4.4B, it is also evident that the bactericidal agents do not 
affect the efficiency of the MTBDRplus assay. All the specimens were known to be pan-
susceptible except samples in lane 2, known to be resistant to rifampicin (weak hybridization on 
rpoBMUT2A), 8 and 12 which were known to be resistant isoniziad (INH).  
 
From these results (figure 4.3 and 4.4), it can be concluded that both OPA and ultraseptin®aktiv 
when used in combination with sputagest activial do not compromise cell walls or the integrity 
of DNA templates for microscopy and PCR amplification respectively.  
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(A) Auramine staining  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-3 Mycobacterial stains of specimens exposed to OPA and Ultraseptin®aktiv  
LEGEND TO FIGURE 4.3 
Figure 4.3 (A and B) shows representative results of ultraseptin®aktiv treated auramine-O (i) and ZN (ii) stains 
exposed to the bactericides for 30 minutes, untreated auramine-O (iii) and ZN (iv), OPA treated auramine-O (v) and 
ZN (vi) stains exposed to the bactericides for 30 minutes. The specimens used for microscopy were all 2+ graded 
sputa. 
 
 
 
 
 
 
(v) (iii) 
   
(i) 
  
(ii) 
(B) Ziehl Neelsen staining 
(iv) (vi) 
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Figure 4-4 Efficiency of PCR amplification after bactericide treatment. 
 
LEGEND TO FIGURE 4.4 
Figure 4.4A: Agarose gel of amplicons of RV2629 gene after sputagest activial liquefied sputum specimens 30 
minutes exposure to OPA and ultraseptin®aktiv (US). Figure 4.4B: MTBDRplus results after sputagest activial 
liquefied sputum specimens 30 minutes exposure to OPA and US exposure.  
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4.2. Factors affecting the MTBDRplus assay 
In an attempt to identify factors which may influence the reliability of the MTBDRplus assay, 
the following experiments were conducted: 
 To determine the effect of underlying non tuberculous mycobacterium (NTM‟s) on the 
detection of drug resistant TB (Materials and Methods – project 2); 
 To determine the limit of detection of drug resistant M. tuberculosis in hetero-resistant 
isolates (Materials and Methods – project 3); 
 To develop a device to prevent amplicon cross contamination during the detection steps 
(Materials and Methods – project 4). 
 
All the tests involving the MTBDRplus assay were repeated twice.  
 
4.2.1. Non-tuberculous mycobacteria  
Pure DNA from a well characterized MDR-TB clinical isolate (R439) of M. tuberculosis with 
known mutations in the katG 315 ACA (INH resistance) and rpoB gene 531 TTG (RIF 
resistance) was mixed with increasing concentrations of NTM DNA.  
 
Figure 4.5 shows representative MTBDRplus results of different ratios made with DNA purified 
from the MDR-TB isolate and (A) M. intracellulare or (B) M. kansasii. From figure 4.5A, the 
MDR-TB strain could still be detected in the background of M. intracelullare at a ratio of 1:10. 
However, the results were interpreted as invalid at a ratio of 1:10 of the MDR-TB isolate in the 
background of M. kansasii as the TUB band is missing (figure 4.5B). During the final stages of 
detection with the MTBDRplus assay, non specific binding to probes often occurs.  It is of note 
that there are two bands numbered 17 and 18 in figure 4.5A on lane 8 but not on the blank in lane 
9. The bands in lane 8 do not affect interpretation of the assay since the TUB band does not come 
up and the drug resistance pattern is also absent. 
 
In a typical diagnostic setting, crude boiled DNA is used for genotypic detection of M. 
tuberculosis and drug resistance testing. To investigate the reliability of the MTBDRplus assay 
on clinical isolates in the background of NTM‟s, crude DNA from the MDR-TB isolate was 
diluted with each of the 10 different NTM‟s in a range of dilutions varying from 1:1 to 1:200.  
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The results in Table 4.2 indicate that as the NTM DNA concentration increases relative to the M. 
tuberculosis DNA concentration, the TUB band which marks presence of M. tuberculosis 
disappears. In the absence of the TUB band the assay is interpreted as invalid. From these results 
it is evident that the MTBDRplus assay cannot reliably detect the presence of M. tuberculosis in 
the presence of NTM‟s which influence the sensitivity of this drug resistance genotyping test.  
 
To further determine the influence of underlying bacterial or mycobacterial species on the 
detection of M. tuberculosis and the corresponding drug resistance pattern, clinical isolates 
previously identified by 16S rRNA and gyrB sequencing that showed mixed infection with M. 
tuberculosis and NTM‟s were evaluated with the MTBDRplus test. Invalid results were obtained 
for 2 samples containing M. terrae and M. triviale (Table 4.3). The Genotype® Mycobacterium 
CM test could not identify M. tuberculosis in all the 5 clinical isolates [data not shown]. In 
addition, further investigation of the reliability of the MTBDRplus assay directly on sputum 
specimens showed that 6/19 were interpreted as invalid when NTM‟s and M. tuberculosis were 
present in the same sample (Table 4.4). Three specimen from 5 of the 19 specimen (961, 337(1), 
848, 278 and 775) identified by the Genotype® Mycobacterium CM to be mix infected yielded 
invalid results on the MTBDRplus assay (table 4.4). The specimen 464 identified as infected 
with M. tuberculosis by 16SrRNA sequencing and M. kansasii by the speciation assay could be 
genotyped for drug resistance whereas specimen 331 identified to contain M. kansasii or gastri 
by 16SrRNA sequencing and M. tuberculosis by the speciation assay could not be interpreted.   
 
In summary, these results suggest that underlying NTM‟s can strongly influence reliability of the 
MTBDRplus assay to detect TB and drug resistance TB. 
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Figure 4-5 MTBDRplus assay results  
LEGEND TO FIGURE 4.5 
Figure 4.5A: Lane 1, MDR-TB DNA isolate (R439), lane 2 M. intracellulare, lane 3-7 Mix DNA of the MDR-TB 
DNA and  M. intracellulare from 1:1, 1:2, 1:3, 1:5 and 1:10 dilution respectively, lane 8-9 are blanks (negative 
control). Figure 4.5B: Lane 1, MDR-TB DNA isolate (R439), lane 2 M. kansasii, lane 3-7 Mix DNA of the MDR-
TB and M. kansasii from 1:1, 1:2, 1:3, 1:5 and 1:10 respectively.  
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Table 4-1 MTBDRplus results for crude DNA mixtures of NTM‟s and the MDR-TB isolate. 
 
LEGEND TO TABLE 4.1 
TUB= presence of M. tuberculosis, X= no hybridization on probe 
 
Table 4-2 Mixed NTM and M. tuberculosis in clinical isolates. 
LEGEND TO TABLE 4.2 
Shows the corresponding 16SrRNA, gyrB gene sequencing and MTBDRplus results of the 4 mixed isolates. 
 
 
NTM Ratio TUB  
INH 
RIF 
MTBDRplus results 
interpretation 
katG inhA 
Wt 
katGMUT 
Wt Mut Wt rpoBMUT3 
1 2 
MDR-TB 1         MDR-TB 
M. peregrinum 1:100       -  Drug resistant to RIF and both resistant and susceptible INH  
M. bovis 1:50       -  
Drug resistant and susceptible to 
INH and RIF resistant 
1:150  -  - - - - - Invalid 
M. abscessus 1:150       -  INH monoresistant 
M. kansasii 1:100       -  
Drug resistant to RIF and both 
resistant and susceptible INH 
1:200  -  - - - - - Invalid 
M. fortuitum 1:50       -  Drug resistant and susceptible to both RIF and INH 
M. chelonae 1:55  -  - - - - - Invalid 
M. intracellulare 1:50  -  - - - - - Invalid 
M. avium 1:100  -  - - - - - Invalid 
M. xenopi 1:50       -  Drug resistant to RIF, both susceptible and resistant to INH 
M. terrae 1:100  -  - - - - - Invalid 
Clinical isolate  16SrRNA sequencing gyrB sequencing MTBDRplus results 
interpretation 
6865 M. kumamotonense M. tuberculosis M. tuberculosis (MDR-TB) 
7426 M. triviale M. tuberculosis No TB, katG MUT1and katG MUT2 detected 
7618 M. terrae M. tuberculosis No TB, susceptible pattern 
7690 M. acapulcensis M. tuberculosis M. tuberculosis susceptible pattern 
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4.2.1.1. MTBDRplus on sputa 
 
Table 4-3 Speciation and drug resistance genotyping of isolates directly from sputum specimens 
without culture. 
 
 
4.2.2. Hetero-resistance 
Reviewing the genotypic data of M. tuberculosis culture from a longitudinal reference bank at 
Stellenbosch University, Tygerberg, Cape Town, South Africa, showed that both wild type and 
mutant cells may be present in the same sputum specimen reflecting hetero-resistance 
(unpublished data: Dr E. Streicher, 2010). To determine the detection limit of the MTBDRplus 
assay for identifying drug resistance in hetero-resistant isolates, purified DNA from a pan-
Sample
 
16S rRNA sequencing gyrB sequencing 
 
Genotype Mycobacterium®CM 
results interpretation  
 
MTBDRplus  
results interpretation 
919 no amplification no amplification M. tuberculosis complex M. tuberculosis (susceptible) 
645 
Uncultured 
Corynebacterium sp.* no amplification 
M. tuberculosis complex M. tuberculosis (susceptible) 
937 M. tuberculosis complex M. tuberculosis M. tuberculosis complex Invalid 
961 M. tuberculosis complex no amplification 
M. avium, M. tuberculosis 
complex,  
M. kansasii 
Invalid 
337 (1) M. tuberculosis complex M. tuberculosis 
M. avium, M. tuberculosis 
complex, 
Invalid 
339  M. tuberculosis complex M. tuberculosis no amplification M. tuberculosis (susceptible) 
848 M. tuberculosis complex no amplification 
M. avium, M. tuberculosis 
complex 
M. tuberculosis (INH Monoresistant) 
472 M. tuberculosis complex no amplification 
 
M. tuberculosis complex 
M. tuberculosis (susceptible) 
773 M. tuberculosis complex no amplification M. tuberculosis complex M. tuberculosis MDR-TB 
516 M. tuberculosis complex M. tuberculosis M. tuberculosis complex Invalid 
278 M. avium no amplification 
M. avium, M. tuberculosis 
complex,  
M. kansasii 
M. tuberculosis (pattern absent) 
775 bad sequencing M. tuberculosis 
M. tuberculosis complex, M. 
fortuitum 
Invalid 
842 M. tuberculosis complex M. tuberculosis no amplification M. tuberculosis (MDR-TB) 
877 M. tuberculosis complex M. tuberculosis no amplification M. tuberculosis (susceptible) 
821 M. tuberculosis complex M. tuberculosis M. tuberculosis complex M. tuberculosis (MDR-TB) 
203 M. tuberculosis complex M. tuberculosis M. tuberculosis complex Invalid 
464 M. tuberculosis complex M. tuberculosis 
 
M. kansasii 
M. tuberculosis (susceptible) 
331 M. kansasii or M. gastric no amplification M. tuberculosis complex Invalid 
913 M. tuberculosis complex M. tuberculosis M. tuberculosis complex M. tuberculosis (susceptible) 
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susceptible and MDR-TB were mixed at different ratio‟s with the amount of DNA of the drug 
resistant isolate kept constant. 
 
Figure 4.6 shows that the MDR-TB RIF and INH resistance markers (rpoBMUT3 and 
katGMUT1) become weaker as a function of increasing wild type M. tuberculosis DNA. 
According to the manufacturer‟s scoring instructions, the MDR-TB strain would be missed when 
the ratio of mutant to wild type exceeds 1:50.  
 
 
Figure 4-6 MTBDRplus assay results for the hetero-resistant ratio mixtures 
 
LEGEND TO FIGURE 1.6 
Lane 1, Pan-susceptible-TB isolate (1260), lane 2 MDR-TB isolate (2126), lane 3-4 Mix DNA of the pan-
susceptible TB and MDR-TB DNA 1:50 and 1:55 dilution respectively, lane 5, blanks (negative control). 
 
4.2.3. Improving the MTBDRplus assay 
PCR-based assays including the MTBDRplus assay are prone to amplicon cross contamination. 
This study aimed to develop a single closed line probe device which will prevent amplicon cross 
contamination during the final steps involved in the detection of genotypes. 
 
Susceptible TB 
MDR-TB 
MDR-TB: Susceptible (1:50) 
MDR-TB: Susceptible (1:55) 
Blank 
4 
3 
1 
2 
5 
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4.2.3.1. Development of a closed line probe assay device 
The device  
The device that was developed consists of wire clumps, rubber tubes, a plastic 4-way connector 
and modified 7ml plastic tubes (figure 4.7). The rubber tubes are divided into 7 compartments by 
wire clumps (figure 4.7). Each compartment contains the reagents used in the different steps 
followed during the final detection steps of the MTBDRplus assay (figure 4.7). These 
compartments respectively contain the hybridization buffer, stringent wash solution, conjugant, 2 
sections for the rinse solution, ddH2O and finally for detection the substrate. A single strip of the 
MTBDRplus membrane is inserted inside the device and closed by the wire clumps. The 
denaturing reagent (20µl) is first mixed with the PCR amplicons (20µl) into a 1ml tube before 
introduction of the two into the 1st chamber. After the hybridization buffer is allowed to mix with 
the membrane, the denatured amplicons (40µl) are injected with a 1ml syringe into the rubber 
tube on the compartment with the membrane. The hybridization buffer and stringent wash 
solution compartments also act as reservoirs. The different reagents are pushed through the wire 
clumps to the compartment containing the membrane and once the respective buffer or wash 
solution is finished, it pushed onto the one of the reservoirs. The single tube device is then placed 
onto a shaking oven at 45ºC during the hybridization and stringent wash steps. The rest of the 
assay is performed at room temperature.  
 
The single tube MTBDRplus device was evaluated on 2 samples, one of which was a pan-
susceptible and the other one was an MDR-TB isolate (figure 4.8). A blank was also included as 
a negative control (figure 4.8). The results indicate that the device could successfully identify 
both the pan-susceptible and MDR-TB pattern correctly and that the blank was also completely 
clean (figure 4.8).  
 
This is a completely sealed device and no amplicons will leak out of the device to cause cross 
contamination with other samples. This device is a prototype for proof of concept and in the long 
term may offer prospects for automation and for patenting.  
 
A single tube line-probe prototype that is user friendly is proposed (figure 4.9). It differs from 
the proof of concept device in that these improvements could be made; (i) linking of the 
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compartments into a linear structure, (ii) use of tap-like clamps instead of wire clamps, (iii) 
incorporation of a reservoir underneath the different compartments with a tap-like clamp within 
the compartment containing the strip membrane, (iv) a plastic sealed well which contains the 
denaturing buffer onto which the PCR product can be injected into with a syringe onto a rubber 
septum.  
 
It is proposed that the device (figure 4.9) can be further improved by (i) creation of a platform 
which links several of these devices in 1 unit (figure 4.10), and by using (ii) a machine which 
opens and closes the taps automatically.  
 
 
Figure 4-7 MTBDRplus prototype of a single tube device. 
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Figure 4-9 MTBDRplus prototype of a single tube device. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-10 Proposed patentable prototype MTBDRplus device 
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CHAPTER 5 
5. Discussion and Conclusion 
 
This study covers two main aspects; it demonstrates a methodology for liquification and 
sterilization of viable mycobacteria in sputum specimens prior to genotypic analysis for rapid 
drug resistance testing outside the confinement of a biosafety level 3 facility as well as highlights 
factor(s) which may influence reliability of the MTBDRplus assay. 
 
Four commercial bactericides (sodium hypochlorite (NaOCl), incidinplus, ortho-phthalaldehyde 
(OPA) and ultraseptin®aktiv) which were reported previously to efficiently sterilize M. 
tuberculosis were identified. They were selected based on their proposed mechanism of action 
according to the chemical structures of their active moieties, lack or low toxicity, cost 
effectiveness and ease of access. The bactericides were evaluated for their bactericidal effect in 
BCG Pasteur cells, a clinical M. tuberculosis isolate (R439) and directly on acid fast bacilli 
(AFB) positive sputum specimens with different quality and bacterial loads. Eight AFB negative 
sputum specimens were included as controls.  
 
The study confirms that sodium hypochlorite (5%), incidinplus (5%), ultraseptin®aktiv (2%), 
and ortho-pthalaldehyde (OPA) (0.5%) are bactericidal against actively growing mycobacteria 
and that their activity is not hindered by the presence of organic matter (in sputum) or bacterial 
load after 30 minute exposure. Our findings are in accordance with previous studies which 
reported cellular degradation and mycobacterial death after exposure to sodium hypochlorite, 
incidinplus, OPA and ultraseptin®aktiv (1,6,7,9,10,14,17). In this study however, bactericidal 
agent(s) which can effectively sterilize mycobacteria without compromising mycobacterial 
stainability or inhibit PCR amplification are required for tuberculosis (TB) diagnosis and rapid 
drug resistance genotyping by PCR-based methods. Although incidinplus and sodium 
hypochlorite are bactericidal, they hindered PCR amplification. OPA was shown to influence 
mycobacterial fluorescence staining as the agent also stains proteins present in sputa resulting in 
background fluorescence noise. Ultraseptin®aktiv was therefore identified as the most promising 
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bactericide which does not negatively impact on staining of mycobacterial cells and also 
provides a template for efficient PCR amplification.  
 
Due to the properties of ultraseptin®aktiv, an algorithm which can be used at primary health care 
clinics with minimal infrastructure was proposed (figure 5.1). A sputum bottle containing 
ultraseptin®aktiv can be used to collect the sputum and microscopy with an LED microscope can 
be done on site while TB suspects or retreatment patients wait at the clinic for the results (figure 
5.1). If AFB positive, treatment can be initiated immediately. Positive specimens can then be 
batched for safe transport and drug resistance genotyping at a central facility. It has previously 
been shown that the turnaround time for routine genotypic diagnosis of TB varies between 2-20 
days (5). The approach outlined in this study has several advantages, i) the protocol can be 
conducted in any primary health care clinic by a person with minimal training, ii) TB diagnosis 
and initiation of treatment can be obtained on the same day while the patient waits at the clinic, 
iii) rapid diagnosis will decrease the percentage of defaulters, iv) safe transport of batched 
samples, v) PCR based drug resistance genotyping can be done directly on sputum specimens, 
vi) rapid drug resistance genotyping will enable rapid proper therapy to patients thereby 
decreasing the rate of transmission to contacts. Liquification of sputum specimens prior to 
bactericidal sterilization is an essential step which may be problematic. This study does not 
provide a defined protocol for initial liquification and subsequent sterilization by 
ultraseptin®aktiv. This problem may be circumvented by using a sputum bottle with a rubber lead 
instead of the conventional plastic lead which would enable injection of ultraseptin®aktiv onto 
the liquified sputum. The sputum bottle presented to the TB suspect would already contain the 
liquification reagent (sputagest activial). Upon subsequent sputum liquification, ultraseptin®aktiv 
would then be injected onto the liquified sputum.  
 
The importance of implementation of a new generation of rapid drug resistance genotyping 
methods has been highlighted by the WHO‟s endorsement of the MTBDRplus assay in 2008 
(16). In a recent study in Tanzania, weak hybridization on the Mycobacterium® genotype CM 
(line probe assay also from Hain-life science) for M. tuberculosis lead to subsequent treatment of 
a patient for TB, however on follow-up after treatment failure presence of a non-tuberculous 
mycobacterial infection caused by M. sherrisii was detected(3). Drug resistance to 1st line drugs 
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of NTM‟s and misclassification of NTM infection as MDR-TB has also been documented 
(12,13). Several studies have also demonstrated and reported the phenomenon of hetero-
resistance (4,8,11,15). The detection limit has thus far only been reported in QT-PCR based 
assays (18). Quantitative RT-PCR based assays have been reported to be highly sensitive at 
detecting hetero-resistance at low DNA concentrations of either allele irrespective of probe 
system used (Taqman MGB, molecular beacon, FRET MGB probes (2,18). Detection was shown 
to be determined primarily based on the amount of each allele and secondly by their respective 
ratios (18).  
 
In this study 3 factors which may negatively impact on the results of this assay were 
investigated: (i) presence of NTM‟s, (ii) hetero-resistance and (iii) cross contamination. The 
results showed that underlying NTM‟s found in local clinical isolates adversely affects the 
MTBDRplus assay in pure or crude DNA and sputum samples. These results suggest that the 
MTBDRplus test cannot be relied upon to test for TB and drug resistance TB in samples with 
underlying NTM‟s. In high TB burden countries where the dual HIV-TB epidemic and 
consequently NTM-TB co-infection are high, the MTBDRplus can therefore not be relied upon. 
Re-evaluation of the reliability of the MTBDRplus assay in settings with high TB and/ NTM-
HIV co-infections is thus required and alternative genotypic tests are therefore needed to validate 
or compliment the MTBDRplus assay. We also report that the detection limit of the MTBDRplus 
assay in hetero-resistance isolates is 1:55. The limitation of this study may include the use of pure 
and crude DNA concentrations as they are not indicative of the number of cells present. Consequently, a 
study using known mixtures of mycobacterial colony forming units instead of purified DNA 
concentrations may be more informative.  
 
Implementation of the MTBDRplus assay may present more problems than anticipated, given 
not only the rudimentary cost and complexity of the tests but also the battle with cross 
contamination during the multiple steps required. Currently only highly specialized laboratories 
are able to perform this test. To combat amplicon cross contamination, a patentable closed tube 
line probe device which enables detection of M. tuberculosis and drug resistance genotyping for 
multiple specimens is proposed. This device is completely closed, thereby preventing any 
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external amplicons from contaminating samples during the final steps of detection of drug 
resistance with the MTBDRplus assay. 
 
In summary, this study identifies a sterilizing agent which can be used at primary health care 
clinics for diagnosis of TB and subsequent drug resistance genotyping by a PCR-based method. 
It also highlights problems with the WHO endorsed MTBDRplus assay and a prototype device to 
overcome amplicon cross contamination during the final detection steps is proposed.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-1 Flow diagram of proposed on site same day sputum smear diagnosis protocol. 
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